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ABSTRACT 
 
Hedgehog proteins (Hh) are morphogens and major mediators in many 
developmental processes. Hh signalling is significant for many aspects of 
embryonic development, whereas dysregulation of this pathway is associated 
with several types of cancers. Hh proteins require dual lipidation and Heparan 
Sulfate Proteoglycans (HSPGs) for their proper distribution and signalling 
activity. 
 
My first aim was to study the role of HSPGs in human (h) Sonic Hedgehog 
(Shh) signalling and clarify the biological function of hShh/HSPGs complexes 
in hShh signalling, by investigating the interaction between human hShh and 
HSPGs. I used DNA mutagenesis and heparin affinity chromatography to 
determine key residues in hShh involved in heparin binding (K37/38 and K178). 
The activity of these mutants was tested by detecting induced Alkaline 
Phosphatase activity in C3H10T1/2 cells and hShh-inducible gene expression 
in PANC1 human pancreatic carcinoma cells. I examined the biological 
function of mutated hShhs (K37/38S, K178S and K37/38/178S) that cannot 
interact with heparin efficiently and showed that they had reduced signalling 
activity compared to wild type hShh and a control mutation (K74S). Also, I 
showed that mutant hShh proteins mediate reduced proliferation and invasion 
of PANC1 cells following hShh RNAi knockdown (KD), and this correlated with 
reduced Shh multimeric complex formation. 
 
Structurally, Shh proteins are unusual in being dually lipid-modified to be fully 
  
3
active. During the post-translational modifications of Shh, N-terminal 
palmitoylation is facilitated by the product (Hhat) of the hedgehog 
acyltransferase gene. I have carried out a thorough analysis of Hhat in PANC1 
cells. First, I characterised an antibody prepared in the lab to hHhat. I 
confirmed the specificity of the antibody by immunoblotting using a 
self-constructed hHhat-EGFP clone, and a control mGup1-EGFP clone. By 
subcellular fractionation and Western blotting I found Hhat to be a membrane 
protein. In addition, I used the hHhat antibody to determine the intracellular 
localisation of hHhat in PANC1 cells by confocal microscopy and showed that 
hHhat localised in ER mainly but not in Golgi apparatus. I confirmed this using 
the hHhat-EGFP clone for fluorescence microscopy in transfected cells. 
 
To illuminate the biological function of palmitoylation of hShh in production of 
active hShh and in the formation of hShh multimeric complex I optimised hHhat 
RNAi knockdown (KD) in PANC1 cells and confirmed this by a cell-based 
palmitoylation assay. Using semi-quantitative RT-PCR and immunoblot 
analyses, I showed that hHhat KD caused decreased signalling through the 
Shh pathway due to reduced production of active hShh. In addition, I 
investigated the effect of the addition of palmitate to hShh on its association 
with cells by comparing hHhat KD cells with control cells. Immunoblotting 
suggests that palmitoylation of Shh improves its ability to associate to cell 
membranes. Using hHhat KD, gel filtration of high molecular weight complexes 
of hShh and immunoblotting of hShh I characterised the role of palmitoylation 
of hShh in multimeric complex formation. Lastly, I investigated the effect of 
hHhat KD on PANC1 proliferation and invasion, showing that it represses 
PANC1 proliferation and invasion. 
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These studies provide a firm basis for understanding the functional roles of 
hShh palmitoylation and its interactions with HSPGs, and provide 
proof-of-principle for targeting these aspects of hShh biology in tumour cell 
therapeutics, specifically in the pancreatic carcinoma context. 
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1. General Introduction 
 
1-1. Hedgehog (Hh) proteins and Hedgehog 
signalling 
1-1-1. Hh proteins 
Overview of Hhs. Hedgehog proteins (Hhs), acting as morphogens, can 
spread from producing cells to specify a diverse range of cell fates from 
segmental patterns in the cuticle of the Drosophila larva to neurons in the 
vertebrate neural tube, in a concentration-dependent manner [1, 2]. The Hh 
signalling pathway was first identified in the 1980s in a large Drosophila screen 
for genes that were required for patterning of the early embryo, originally 
discovered through the Drosophila segmental pattern mutation hedgehog. In 
mammals, all three members of Hh family proteins, Sonic (Shh), Indian (Ihh), 
and Desert (Dhh) Hedgehog, display a variety of roles in embryonic 
development, adult homeostasis, and cancer [3, 4, 5]. Although the term “Hh” 
strictly only applies to Drosophila I use the term “Hhs” here for simplicity to 
also encompass vertebrate hedgehog proteins, unless the distinction is 
crucial. 
 
To date, the Hh signalling pathway is one of the most critical signalling 
pathways in both vertebrates and invertebrates [6, 7]. Perturbations to the Hh 
signalling pathway manifest themselves in disease; for instance, over-activity 
of the pathway can lead to oncogenesis and lower activity of the pathway can 
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result in developmental malformations [8, 9]. During differentiation and 
tumorigenesis, diverse targets of Hh signalling are involved in cell adhesion, 
signal transduction, cell cycle, apoptosis and angiogenesis [10] (Section 1-1-4, 
The significance of Hh/Shh pathway and Signalling components that cause 
cancer). In addition, it has been estimated that 25% of all human tumours 
require Hh signalling to maintain tumour cell viability. Therefore, to establish 
potent Hh inhibitors and biomarkers are significant goals for diagnosis and 
treatment of diverse human tumours. 
 
Post-translational modifications of Hhs. The most atypical feature of Hh 
proteins is their post-translational modifications (Fig. 1-1), including 
autocatalytic cleavage, the unique N-terminal palmitoylation and C-terminal 
cholesterol attachment [11]. Hhs are the best established examples of 
cholesteroylated proteins in nature. In Drosophila, the approximately 45 kDa 
Hh precursor has its signal sequence (SS, from a.a.1 to a.a.23), removed 
co-translationally. It is now believed that Hhs are then palmitoylated on their 
highly conserved N-terminal Cys residue in the endoplasmic reticulum (ER) or 
Golgi complex [12]. A ~19 kDa N-terminal fragment (Hh-N) and a ~25 kDa 
C-terminal fragment (Hh-C) are subsequently yielded by autocatalytic 
cleavage catalysed by Hh-C [11]. Concurrently, a cholesterol molecule is 
covalently attached to the C-terminus of Hh-N thus forming the mature form of 
Hh, Hh-Np [14]. Unlike Hh-C, Hh-N contains all the signalling functions. 
  
There is evidence that the role of N-terminal acylation of Hh-N is to enhance 
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the affinity of Hh to biological membranes and to regulate the distribution of the 
Hh signal [6, 14]. In addition, according to mammalian studies, cholesterol 
covalently attached to Hh might improve target biological activity by facilitating 
the interaction between Hh and its receptor Patched (Ptc) [16]. Hence, these 
lipid modifications are significant for Hh intracellular trafficking and to its 
extracellular concentration regulation. 
 
 
(from Mol. Mem, Biol. 2009. 26(1-2): 104-113) 
 
Figure 1-1. Post-translational modifications of Hh. The Hedgehog gene is 
expressed as a 45 kDa precursor that undergoes both dual lipidation as well as 
internal autoprocessing at a conserved sequence. After its signal peptide 
(orange region) is removed co-translationally, the precursor is palmitoylated by 
adding a Palmitoyl-CoenzymeA (Pal-CoA) to the new N-terminal cysteine. This 
N-palmitoylation is facilitated by Hhat and it has been suggested that an 
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intramolecular S-to-N shift occurs, transferring thioester linkage to amide 
linkage. Then, there is an autocatalytic cleavage at the GCF sequence 
catalysed by the C-terminal domain of the precursor (gray region) to produce a 
19 kDa signalling domain Hh-N and a 25 kDa Hh-C. During the autocleavage 
event, Hh-N is modified by cholesterol at its carboxy-terminal glycine to form a 
fully active Hh-Np. Unlike Hh-C, Hh-Np contains all known signalling activities.  
 
 
1-1-2. Hh signalling pathway components 
Overview of Hh signalling. Interestingly, Hh signalling is mediated by a series 
of inhibitory steps. For release from producing cells, cholesterol-modified Hhs 
require the activity of another multispanning membrane protein Dispatched 
(Disp) (13,15) and hence this protein is required for long range Hh/Shh 
signalling. Disp, a 12-pass transmembrane protein, is related to the 
resistance-nodulation division (RND) family of bacterial proton-driven pumps, 
since mutations disturbing conserved residues important for the function of 
bacterial transporters prevent Shh release [17]. Disp also contains a 
sterol-sensing domain which may play a role in binding cholesterol attached to 
Hhs. Interactions with heparan sulfate proteoglycans (HSPGs) are likely 
involved as well (Section 1-2-1, HSPGs in cell-cell signalling and Section 
1-2-2). The N-terminal end of Shh contains a Cardin-Weintraub sequence 
responsible for the binding of the morphogen to HSPGs and mutations in this 
domain are linked to a decrease in the proliferative activity induced by ShhN 
on cerebellar granule cell precursors [18]. After secretion, the diffusion of all 
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three Hh ligands is limited by binding to the glycoprotein Hedgehog-interacting 
protein (Hhip), Patched 1 (Ptc1) and Patched 2 (Ptc2) transmembrane 
receptors, all of which are expressed on Hh-responsive cells.   
 
In Hh-receiving cells, Hh mediates its action via two transmembrane proteins: 
Patched (Ptc) displaying a transporter-like structure and Smoothened (Smo) a 
putative member of the G protein-coupled receptor superfamily [219] (Fig. 1-2). 
Ptc, a 12-transmembrane protein, is the receptor for Hh through its 2 large 
extracellular loops. On the other hand, Smo, a 7-transmembrane protein, is a 
positive transducer of Hh signalling, and it is believed that Ptc directly inhibits 
its biological activity. Although the exact details of ligand-receptor signalling 
are still under debate, the current model proposes that in the absence of 
ligands, Smo is impeded from signalling by Ptc. On the contrary, in the 
presence of active Hh, Hh binds to Ptc and this releases Smo to activate 
downstream signalling [19] (Section 1-1-4, The significance of Hh/Shh 
pathway). As a consequence, Smo becomes active and leads to a complex 
signalling cascade involving the transcription factors of the Gli family - the 
vertebrate homologues of the Drosophila Cubitus interruptus (Ci) [28]. 
Interestingly, the organisation of the transmembrane domains of Ptc is similar 
to several cholesterol-binding proteins. This suggests that Ptc is not only a 
cholesterol-binding protein, but also a potential key to restrain unmodified Hh 
from interfering with signalling [20, 21]. 
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Figure 1-2. One model for how Hh multimers affect signalling in opposite 
directions. (A) In the absence of the ligand Hh, the receptor Ptc maintains 
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Smo in a compartment where it cannot engage with the downstream signalling 
machinery. Because of this, the Gli-modulating Fused-SuFu-Gli complex 
remains associated with the cytoskeleton (black bar). Gli is then cleaved, 
releasing the inactive form (GliI) that enters the nucleus and represses Hh 
target genes. (B) In Drosophila, internalisation of the Hh–Ptc complex 
promotes the activation of Smo. As a result, full length Gli is released from the 
Fused-SuFu-Gli complex and enters the nucleus to activate transcription, and 
subsequently stimulate the signalling activity. 
 
 
Downstream signalling. Three vertebrate Gli genes — Gli1, Gli2 and Gli3 — 
have been identified. These proteins contain five zinc-finger DNA-binding 
domains and differ by their N-terminal domains [22,23,24]. Gli1 is considered 
as a means to amplify the Hh response rather than a direct effector of the Hh 
transduction machinery. However, Gli1 is a target gene of the pathway and is 
classically used as a convenient readout for the pathway activation. Gli2 would 
function mainly as a transcriptional activator, but also could display a repressor 
activity in specific contexts. Conversely, Gli3 mainly functions as a 
transcriptional repressor even though recent studies have also shown that Gli3 
can act as an activator in vivo [22,23,24]. Gli proteins are post-translationally 
modified, and cleavage of the whole proteins results in N-terminally-truncated 
activator and C-terminally-truncated repressor fragments. The details of Gli 
activation remain obscure. However, evidence indicates that in the absence of 
ligands, Gli proteins are linked to the cytoskeleton by interaction with a 
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multiprotein complex that includes Fused (Fu) and Suppressor of Fused 
(SuFu). SuFu, a negative regulator of Shh signalling, interacts with the three 
vertebrate Gli proteins to retain them in the cytosol [178, 179] and also to 
control Gli function at nuclear level [25,26]. Following ligand binding, Gli 
proteins translocate into the nucleus where they control transcription of target 
genes. It is important to note that several inhibitors of the pathway are encoded 
by transcriptional target genes, including Ptc, Gli1, Gli2, Gli3 and Hhip [24,27]. 
Hence, ligand-induced activation creates a negative feedback loop that 
restricts the extent of Hh signalling. As a consequence, Hh signalling is 
regulated at different levels by components of the pathway — a peculiar 
phenomenon that indicates that tight control of its activity is crucial for proper 
function. 
 
 
1-1-3. Membrane-bound O-acyltransferase (MBOAT) family 
Overview of MBOAT family. Members of the membrane-bound 
O-acyltransferases (MBOAT, Fig. 4-1) family are multispanning 
transmembrane proteins that usually catalyse the addition of a fatty acid to a 
hydroxyl group, typically of membrane-associated substrates such as lipids 
[29]. Studies based on protein purification and molecular characterisation are 
limited due to the presence of multiple transmembrane domains in MBOAT 
family proteins raising difficulties in reconstitution in vitro. Recent genetic 
screens for patterning mutations in Drosophila have supported the idea of 
enzyme-catalysed acylation by identifying a single, novel gene - Hedgehog 
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Acyltransferase (Hhat) that is required for production of an active Hedgehog 
signal in vivo [30-33]. Molecular characterisation of this gene revealed that it 
encodes a protein belonging to the MBOAT family of enzymes; the Wingless 
(Wg)/Wnt pathway gene porcupine (porc) is also a member of this family. 
Reports suggested that Porc is responsible for the palmitoylation of Wg, a 
morphogen involved in embryonic patterning in Drosophila, and its human 
homologues Wnts. Besides Hhat and Porc, only one other MBOAT protein, 
ghrelin O-acyltransferase (GOAT) has been identified in transferring fatty acids 
to target proteins or peptides. GOAT has been identified in metabolic activation 
of the 28-residue peptide hormone ghrelin by specifically acylating ghrelin on 
its critical serine-3 residue with medium chain fatty acids (FAs) [61,64]. 
 
Study of Hhat. The Hh family of secreted signalling proteins has been studied 
in a wide array of metazoan organisms. During post-translational modification 
of Hhs, N-palmitoylation occurs in the amino-terminal signalling domain of both 
Drosophila Hh and human Shh via amide linkage. This N-terminal palmitate is 
added to a highly conserved cysteine in a CGPGP motif exposed by signal 
peptide cleavage. It has been suggested that S-acylation of the cysteine 
sulphydryl could initially occur followed by a rapid and efficient intramolecular 
S- to N-acyl shift [34] and this is still a plausible mechanism of the N-terminal 
acylation. N-terminal palmitoylation of Hhs is facilitated by the product (Hhat) 
of the hedgehog acyltransferase gene (also known as skinny hedgehog, 
sightless, central missing or rasp) [31,33,35]. This multi-spanning 
transmembrane acyltransferase is directly and specifically required for the 
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N-terminal addition of palmitate to Hhs. Hhat has recently been definitively 
shown by Buglino and Resh to be a specific acyltransferase for Shh using an in 
vitro assay with purified components [12]. The reaction is clearly enzymatic 
and requires a free N-terminal cysteine and Pal-CoA as cosubstrate, although 
the concentration of Pal-CoA used is much higher than that found in cells. This 
could be explained by the presence of acylCoA binding protein (ACBP) in cells 
which may present Pal-CoA to Hhat [36]. In Drosophila, RNAi-mediated Hhat 
knockdown reduces N-terminal acylation of Hh in vivo and causes a reduction 
in cell association as indicated by a significant increase in release of Hh 
protein into the culture medium [31]. This study has implications not only for Hh 
generation and packaging but also in the distribution and reception of the Hh 
signalling.  
 
Porcupine (Porc). In addition, Hhat shares homology with Porc in Drosophila 
and its Caenorhabditis elegans homologue Mom-1, and with GOAT, putative 
acyltransferases that are also part of the MBOAT family and are responsible 
for the palmitoylation of Wg, a morphogen involved in embryonic patterning in 
Drosophila, and its human homologues Wnts, and of ghrelin, respectively. This 
homology includes the conserved histidine residue that may be involved in the 
active site of the putative acyltransferase (Fig. 4-1). Both the Hh and Wnt 
pathways have emerged as playing an important role in a growing number of 
types of cancer [42–44] in which a general feature is unregulated activation of 
these pathways. On the other hand, both signalling pathways are emerging as 
playing homeostatic roles in the maintenance of postembryonic tissues (e.g. 
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stem cell maintenance in particular tissues [37–41] and possible participation 
in tissue repair in response to injury [42]).  
 
As shown for Hhat, Porc is required in Wg/Wnt-producing cells for generating 
the fully functional signalling [45,46]. Early reports suggested that Porc is 
required for Wnt protein secretion, and others have demonstrated that the 
activity influences the N-linked glycosylation of the protein [47,48]. By 
metabolic labeling and mass spectrometric-based mapping analyses, Willert et 
al. [49] reported that both vertebrate and Drosophila Wg/Wnt proteins are 
modified by palmitate at a conserved cysteine residue. Mutation of this 
cysteine causes a loss of palmitate incorporation, and this mutation as well as 
enzymatic removal of the palmitate both reduce the biological activity of the 
protein, suggesting the function of Wg/Wnt acylation is related to interactions 
with receptor, membranes and lipoprotein particles (e.g. palmitoylation of 
Wnt5a is required for binding to its receptor Fz5 and activation of intracellular 
signalling [50]). It has been shown that almost all targets of the MBOAT family 
appear to be dually acylated in the lumen of the secretory pathway [51,52]. 
The most N-terminal cysteine residue after the signal sequence (e.g. Cys77 in 
murine Wnt3a and Cys93 in Drosophila Wg) is usually S-acylated [53]. 
Recently, a second acylated residue has been identified as Ser209 in murine 
Wnt3a [54] which is O-esterified with the monounsaturated fatty acid 
palmitoleic acid (C16:1). Interestingly, acylation of Ser209 is required for 
secretion of Wnt3a and possibly for Cys77 acylation, but Ser209 acylation is 
not dependent on acylation of Cys77. Also, for Drosophila Wg, Cys93 acylation 
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is essential for signalling activity and transport to the cell surface whereas 
Ser293 acylation seems to be less important for secretion but is still required 
for maximal signalling activity [52], implying the crucial role of membrane 
association. Since cysteine acylation is dependent on previous serine 
acylation [52,55] it is possible that Porc is responsible for the serine acylation 
but that the cysteine acylation is subsequently performed by a different 
enzyme. In that case, serine acylation would be permissive for cysteine 
acylation. It is important to characterise the biochemical function of Porc, as 
multiple Wnts play key roles in tumour formation
 
and maintenance and human 
Porc itself has been found to be mutated in developmental disorders such as 
Focal Dermal Hypoplasia [56,57]. Hence, Porc is a potential therapeutic target 
in several human diseases. Interestingly, acylation is not a universal 
modification in the Wg/Wnt family e.g. Drosophila WntD has very recently been 
shown not to be acylated [58], in contradiction to an earlier report form the 
same laboratory [53]. Although WntD contains the conserved N-terminal Cys 
residue it does not contain an equivalent Ser209 residue, again suggesting 
that cysteine acylation is dependent on prior serine acylation. Finally, the dual 
acylation of Wg/Wnt proteins may also facilitate their interaction with 
membrane lipid microdomains/lipid rafts that could be the site of assembly of 
the lipoprotein transport packages [59], hence the dependence of Wg 
long-range secretion on the raft-resident protein reggie-1/flotillin-2 [60]. 
 
GOAT. Another MBOAT family member - ghrelin O-acyltransferase, GOAT - 
was identified and characterised simultaneously in 2008 by two independent 
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groups [61,62]. Ghrelin, like many other peptide hormones, is generated from 
a precursor protein - preproghrelin contains 117 amino acids [63, 65]. After 
removing the signal sequence by cleavage at amino acid-23, the proghrelin 
peptide sequence (94 amino acids) has an N-terminal glycine residue. The 
prohormone convertase PC1/3 then cleaves proghrelin after arginine-28, 
generating the mature 28-amino acid ghrelin peptide [66]. During 
posttranslational modification of the ghrelin precursor protein, serine-3 is 
acylated with an eight carbon fatty acid (octanoate). Octanoylation of ghrelin is 
a specific modification that is required for ghrelin to bind to its receptor 
GHS-R1a and to exert most of its biological properties. The enzyme 
responsible for the octanoylation of ghrelin is ghrelin O-acyltransferase (GOAT) 
[67,68] that is also named membrane bound O-acyltransferase 4 (MBOAT4).  
The activity of GOAT is dependent on its Asn and His putative catalytic 
residues typical of the MBOAT family. GOAT knockout and GOAT transgenic 
mice have been generated [69] and are indeed important tools for 
understanding the physiological relevance of GOAT. In 2008, Yang et al. 
published work involving an in vitro biochemical assay and INS-1 cells to test 
the sequence requirements for substrate recognition by GOAT [63]. By using 
mutagenesis, they demonstrated that the N-terminal glycine-1, serine-3, and 
phenylalanine-4 of ghrelin are crucial for GOAT recognition [63]. These three 
amino acids in the ghrelin sequence are absolutely conserved in all 
vertebrates [65]. An analogue acylated in amide linkage at position 3, [Dap3] 
octanoyl-ghrelin (1-5)-amide, is particularly effective as an end product 
inhibitor. On the other hand, modification of dietary medium chain FAs can
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modulate ghrelin acylation and activity in vivo [70], so reduction in these could 
suppress appetite thus having applications in obesity and type II diabetes, 
whereas supplementation could promote appetite and have applications in 
eating disorders such as anorexia, although the substantial psychological 
component of these disorders cannot be underestimated. Since ghrelin has 
metabolic, endocrine, and clinical significance, the complete regulation of the 
ghrelin–GOAT system is a significant mechanism involved in the pathogenesis 
of obesity and diabetes. Ultimately, a better understanding of GOAT regulation 
and especially the development of pharmacological GOAT inhibitors or 
activators will be crucial for understanding the true function of the 
GOAT–ghrelin system and its potential as a pharmacologically treatable target. 
In addition, these studies may provide information that is applicable to the 
design of inhibitors for Porc and Hhat, for example taking advantage of the 
highly conserved N-terminal acylation site CysGlyProGlyArgGlyPhe of 
mammalian Hh proteins. 
 
As for Hhat and Porc, GOAT presumably requires as its cosubstrate a fatty 
acyl coenzyme A (FACoA). This creates a topological problem as FACoAs are 
predominantly localised in the cytoplasm and are bound to the high affinity 
ACBP, possibly to prevent these highly reactive thioesters from reacting 
nonspecifically with cell components such as proteins [36]. Thus, to react with 
the lumenal substrates (Hhs, Wg/Wnts and proghrelin) the FACoA would need 
to be transported across the ER membrane. The multispanning topology of the 
MBOAT members could facilitate this transport in as yet unknown ways, as 
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suggested recently for GOAT [62] and as early as 1996 for Porc [46], and if so 
this could provide another therapeutic target activity.  
 
 
1-1-4. Hh/Shh signalling in cancer 
The significance of Hh/Shh pathway. Hh/Shh acts as a morphogen to induce 
distinct transcriptional programmes and cell types based upon its local 
concentration [1]. Hh/Shh signalling is involved in many patterning processes. 
The primary cilium is a non-motile microtubule-based structure that extends 
from membrane-docked basal bodies in most mammalian cell types. It has 
recently become clear that regulation of Hh signalling in mouse and zebrafish 
has a conserved role in ciliogenesis which is essential for Hh signalling, but not 
in Drosophila [220]. A requirement for the cilium in Hh pathway was first 
suggested on the basis of mutagenesis screens in mice, which showed that 
genes required for ciliogenesis are also required for Hh signal transduction 
[220].  
 
In vertebrates, Hh/Shh signalling ensures the development of many tissue 
types, including hematopoietic [71,72], osteoblastic [73,74], retinal [75,76], 
gastrointestinal [77,78], hair [87,88], neuronal [79,80], limb [81,82] and 
prostatic tissue [83,84]. Among these, Shh in the zone of polarising activity 
coordinately expressed with FGF4 in the apical ectodermal ridge to facilitate 
limb-bud development [81]. Also, Shh facilitates the expression of different 
transcription factors (TFs) in the developing neural tube, e.g. Pax6, Nkx2.2 and 
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Olig2, through controlling its concentration gradient along the dorsal – ventral 
axis [85,86]. Furthermore, in the developing neural tube different combinations 
of Shh-dependent TFs induce the fates of various cells types, including motor, 
floor plate, and dopaminergic neurons. Based on recent findings on 
Gli-stimulated transcription of cyclin B1 and cyclin D1, it suggests that via 
regulating cyclin-dependent cell proliferation, the pathway is able to guide 
tissue specification as well as tissue maintenance [89,90]. Also, the pathway 
provides a good model to show how the same molecular machinery can lead 
to different fates in different developmental tissues. 
  
Signalling components that cause cancer. Given significance of the Hh 
pathway in tissue patterning and cell maintenance, mutations in Hh pathway 
genes or events causing misregulation of the pathway are associated with 
certain cancers, e.g. a distinct subset of tumours in mice and human is 
identified by mutations in Hh signalling components. Also, inappropriate 
Hh/Shh signalling is frequently related to tumour initiation and maintenance, 
e.g. basal cell carcinomas (BCCs) and medulloblastomas are often 
characterised by Ptc1 inactivation or constitutive activation of Smo [91-94].  
 
Based on the hypothesis that constitutive activation of Hh/Shh signalling 
induces tumorigenesis, mutations in Shh have been characterised in a small 
percentage of BCC, medulloblastoma and also in one case of breast 
carcinoma cells [95]. In the majority of BCCs, gene expression profiling shows 
increased transcription of target genes of the Shh pathway [100]. That Shh 
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acts as a dominant oncogene was shown in studies from mice and humans, in 
which ectopic expression of Shh results in BCC [95,96]. Mutations in Ptc1 
leading to constitutive activation of Smo were found in many BCCs. Patients 
with Gorlin syndrome (also known as basal-cell nevus syndrome, BCNS) have 
one defective Ptc1 allele, and are characterised by a high incidence of BCCs, 
medulloblastomas or other developmental defects. In transgenic mice, Shh 
overexpression driven by a constitutive Keratin 14 (K14) promoter causes 
development of BCC-like lesions with no UV exposure [101]. Abnormal 
development was observed from many of the K14-Shh mice, including shorter 
limbs, excess digits and improperly formed neural tubes. Similarly, 
constitutively active mutations of Smo have been found in 10–20% of BCCs. In 
addition, ectopic expression of Gli1 or Gli2 in the skin of Xenopus tadpoles or 
mice results in tumour formation, indicating that activating most downstream 
components of the pathway is sufficient to initiate tumour growth [97-99]. 
 
Medulloblastoma - the most common type of brain tumour in the young 
population – is associated with increased Gli1 expression in the cerebellum 
and with high levels of morbidity in the range of 50% even under treatment 
[100]. In medulloblastoma, it is often found mutations of Smo or Ptc1 in 
neuronal cells in the cerebellum which causes constitutive activation of Smo. 
Mutations in SuFu have been associated with an increased risk of 
medulloblastoma in humans [102]. Transgenic mice with Ptc1+/- and p53-/- 
often develop medulloblastoma. 
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Like in the lung, Hh signalling is active during pancreas organogenesis [103] 
and low-level expression of Hip1, Ptch1, Smo, Ihh and Dhh has been detected 
within mature islets and cultured cell lines [104,105,106]. Maintaining active Hh 
signalling via a paracrine mechanism, with the cancer cells overexpressing 
Shh ligand and adjacent stromal cells being competent to receive the signal, 
has been tested in certain pancreatic cancer cell lines both in vitro and in vivo.  
In in vitro co-culture assays, the pancreatic cancer cell lines PANC-1 and 
ASPC-1 (which overexpress Shh) were able to activate Gli transcription in 
co-cultured 10T1/2 cells [107]. More importantly, implanting the human 
pancreatic cancer cell line HPAF-II into Ptc1-LacZ mice, LacZ staining 
indicated upregulated Ptc1 in the stromal cells surrounding the implant, but not 
in the tumour tissue. Recent evidence also indicates that downregulated Hh 
signalling not only causes tumour formation, but also is required for tumour 
maintenance, as transformed cells need active Hh continuously for survival 
and growth. Analysis of 26 human pancreatic adenocarcinoma cell lines 
showed that all lines express Hh target genes, and induced apoptosis and 
decreased proliferation in 50% of the cell lines tested were observed during 
cyclopamine treatment - a naturally occurring cholesterol analogue that inhibits 
Smo [108]. In pancreatic ductal adenocarcinoma (PDAC), the Shh pathway is 
found over-activated [109]. Also, gene expression studies in PDAC precursor 
lesions have demonstrated high expression levels of Shh target genes, 
including Gli1 and Ptc1, and cyclin D1. Though the molecular basis of 
pancreatic cancer is now better understood, the development of new 
diagnostic approaches and efficient treatments is still poor. PDAC remains one 
  
37
of the most difficult cancers to treat. In 2000, there were 217,000 new cases of 
pancreatic cancer and 213,000 deaths world wide and 60,139 new patients 
(10.4% of all digestive tract cancers) and 64,801 deaths in Europe [223]. In 
2006 there were 33,730 new cases and 32,300 deaths in the USA [223].  
 
Shh signalling also plays a role in the pathogenesis of chronic myelogenous 
leukemia (CML), gliomas, and multiple myeloma (MM) [110-112]. Reya and 
colleagues developed mice that lacked expression of Smo. When the mice 
were implanted with CML stem cells, the frequency of CML was reduced by 
nearly 50% relative to mice expressing wild-type (WT) Smo [110]. Additionally, 
mice expressing a constitutively activated form of Smo had a fourfold increase 
in CML stem cell population relative to mice expressing WT Smo. These data 
provide evidence that Hh inhibition impedes CML progression by affecting 
CML stem cells. In human glioma [113] - a central nervous system (CNS) 
tumour - the transcription factor Gli1 was overexpressed.  When treated with 
the Smo inhibitor cyclopamine, glioma stem cell growth is inhibited [111], e.g. 
cyclopamine-treated CD133+ glioma stem cells showed diminished cell 
population by almost 50% relative to mock treatment and reduced Gli1 and 
Ptch1 mRNA levels by 50% and 40%, respectively. Myeloma (MM) is a 
non-Gorlin cancer affecting plasma cells [112]. In tumourgenic MM cells, 
transcript levels of Smo, Gli1, and Ptc1 were found strongly upregulated 
compared to control healthy cells, as well as in MM stem cells (but not for Ptc1). 
Cyclopamine treatment reduced MM stem cell population and promoted 
differentiation of MM stem cells into non-proliferating mature MM cells [112]. 
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To sum up, active Shh signalling induces the maintenance and proliferation of 
cancer stem cells in CML, glioma, and MM. 
  
 
 
1-2.  Functions of Heparan sulphate proteoglycans 
(HSPGs) in Hh/Shh signalling 
1-2-1. HSPGs overview 
HSPGs. Intensive biochemical and genetic studies have shown that HSPGs 
have crucial roles in many developmental signalling systems involved in cell 
fate determination and multi-cellular organisms development, such as Wnt, Hh, 
transforming growth factor-β (TGF-β ) and fibroblast growth factor (FGF) 
pathways [114]. HSPGs are evolutionarily highly conserved molecules and are 
expressed in most animal cells. HSPGs are extracellular matrix and cell 
surface macromolecules that consist of a core protein and one or more HS 
glycosaminoglycan (GAG) chains (Fig. 1-3). Based on the structure of the 
protein cores, these molecules can be classified into several families [115]. 
Syndecans and glypicans are two major cell surface HSPGs; both are integral 
membrane proteins. Syndecans are transmembrane proteins that contain a 
highly conserved short [34–38 residue] carboxy-terminal cytoplasmic domain 
[115], whereas glypicans are disulfide-stabilised globular proteins linked to the 
plasma membrane by a Glycosylphosphatidylinositol (GPI) linkage [115]. 
Other cell surface HSPGs such as CD44 and Betaglycan seems to have a less 
significant role in ligand interactions. Interestingly, while glypicans bear 
exclusively HS chains, syndecans are able to associate with both HS and 
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chondroitin sulfate (CS). Besides syndecans and glypicans, perlecans are a 
group of secreted HSPGs that are mainly distributed in the extracellular matrix 
(ECM) and, like syndecans, can have attached CS chains in some cases [116].  
 
 
 
 
Figure 1-3. Cartoon representation of three categories of HSPGs. A 
syndecan with both HS and CS GAGs represents the membrane-spanning 
class of HSPGs. A glypican is depicted to represent the GPI-linked HSPG 
family. Perlecan shown carrying HS GAGs represents a group of secreted 
ECM HSPGs. 
 
 
Biosynthesis of HS GAG chains. Both core proteins and enzymes involved 
in the biosynthesis of HS are conserved in vertebrates and invertebrates 
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[117,118]. A single syndecan gene, two glypican genes and a perlecan 
homologue have been identified in Drosophila. Biosynthesis of HS starts in the 
Golgi apparatus, at its attachment site to a core protein, which contains 
between 2 and 4 Ser-Gly sequences, and is further modified by sulphations 
and epimerisations before transport to the cell surface. Firstly, an 
oligosaccharide primer is attached to specific serine residues on a 
proteoglycan core protein. This primer serves as a substrate for the 
co-polymerases that add alternating linked D-glucuronic acid (GlcA) and 
N-acetyl-D-glucosamine (GlcNAc) residues, resulting in repeating disaccharide 
chains of about 100 or more sugar units in length [115]. This polymer is 
subsequently modified via a series of reactions; e.g. both N-deacetylation and 
N- sulphation of GlcNAc units, epimerisation of GlcA to L-iduronic acid (IdoA) 
residues, and O-sulphation at various positions [114,115]. These additional 
modifications in HS chains create enormous heterogeneity in HS structure, 
and allow HSPGs to bind a wide variety of extracellular ligands. The proteins 
responsible for the addition of alternating GlcA and GlcNAc residues after 
initiation of the heparan chain are encoded by tout-velu (ttv/Ext1), 
sister-of-tout-velu (sotv/Ext2), and brother-of-tout-velu (botv/Extl3) in 
Drosophila [114]. 
 
HSPGs in cell-cell signalling. Studies supporting a role of HSPGs as 
co-receptors have come from genetic mutants in model organisms. Analyses 
of the mutants have demonstrated that HSPGs have additional roles as 
transducers of patterning information as well as regulators of morphogen 
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gradient formation. Despite the fact that a majority of these mutants have 
defects in cell-cell signalling, HSPGs have also been known to regulate 
numerous biological functions, including organisation of the cytoskeleton [127], 
migration [120,124], inflammation [122], metastasis [123] and synapse 
formation [125]. The role of HSPGs as FGF co-receptors has been well studied 
demonstrating an essential role of HS upstream of FGF signal transduction 
[126]. The model suggests that via specifically binding both the FGF ligand and 
its receptor to form ligands-receptor complexes, HS mediates the formation of 
an active transit complex and activates FGF signalling [121]. HSPGs are 
generally thought to function as “cell-autonomous” co-receptors on the same 
cell surface, but also function “cell-nonautonomously”; e.g. FGF signalling can 
be stimulated in cell culture by HS attached to a different cell [128]. In addition, 
recent studies suggest that HSPGs can have a more direct role in mediating 
signal transduction via cytoplasmic kinases, adapter proteins, or even the 
HSPG cytoplasmic domain itself to mediate signalling. For example, 
Syndecan-4 can recruit and activate PKC α  by forming multimers in the 
presence of phosphatidylinositol 4,5-bisphosphate (PIP2) [129]. The PKC α
recruitment seems to be an essential downstream step in FGF2 signalling in 
endothelial cell culture and dependent on binding both PIP2 and a 
PDZ-containing protein [130]. Finally, HSPGs may also present as morphogen 
regulators. Secreted moleculars are often referred to as morphogens due to 
their activity in a symmetric extracellular distribution and in determining 
multiple cell fates across a tissue, as a consequence of their graded levels. 
One example is that HS mediates Hh function in embryos via regulating Hh 
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distribution across developing tissues [131]. In addition, analysis of 
loss-of-function mutations in Dally and Dally-like protein (Dlp, the Drosophila 
homologue of mammalian glypican-4/6) indicate that these molecules are in 
involved in Hh diffusion [222], and Dlp was also shown to be needed for the 
reception of Hh in cultured cells and embryos of Drosophila [137,173]. Also, 
different Drosophila mutants suggest a role of HS and Dlp in the extracellular 
distribution of Wnts [132,133,134]. On the other hand, Dally has a dual role in 
regulating Decapentaplegic (a Drosophila TGFβ  family member) signalling, 
as a co-receptor and as a regulator of morphogen gradients [135]. 
 
 
1-2-2. Multiple roles for HSPGs in Hh/Shh signalling 
The potency of HSPGs in Drosophila Hh and vertebrate Shh signalling. 
Developmental and biochemical studies in Drosophila and vertebrate systems 
have proposed that HSPGs are essential for proper Hh distribution, 
stabilisation and signalling activity [115,136]. HSPGs are also believed to 
facilitate the presentation of Hh ligand to signal-receiving cells and participate 
in promoting cell surface microdomains/lipid rafts in which the crucial 
molecules are assembled into functional complexes [114]. Key pieces of 
evidence are as follows: 
 
1) Flies deficient in ttv, sotv or botv (encoding enzymes involved in GAG 
biosynthesis) display embryonic phenotypes indicative of disturbed Hh, 
Wg/Wnt, Bone morphogenetic protein (Bmp) and FGF signalling. In the wing 
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imaginal disc, Hh protein is not able to diffuse completely in ttv, botv, or sotv 
mutant clones; this phenomenon is more pronounced in ttv-ptc or ttv-botv 
double mutants [114]. In addition, loss of Hh protein from the ECM in ttv, sotv 
and botv clones implies a role of HSPGs in protecting Hh from degradative 
processes, or alternatively HSPGs may participate in releasing Hh ligand from 
producing cells. 2) Two core HSPG proteins in Drosophila, the glypicans Dally 
and Dlp, have been shown to be functional in the movement and reception of 
the Hh signal. Dally and Dlp play roles in facilitating Hh movement from its sites 
of synthesis [114]. In contrast, RNAi of dlp (but not dally) in clone-8 cells results 
in a loss of responsiveness to exogenous Hh, but this defect can be rescued by 
cell-autonomous expression of Hh [137]. Similarly, it has been shown in GPC3 
(one of the six mammalian glypicans) null mice that expression of Hh target 
genes is increased in a variety of tissues, consistent with the finding that GPC3 
competes with Ptc for binding with Shh at the cell surface and induces 
endocytosis and degradation of a Shh-GPC3 complex, removing Shh from the 
cell surface [138,139]. Nevertheless, GPC3 plays a positive role in Wnt 
signalling [140]. Conflicting data exist concerning the role of HSPGs in 
achieving maximal Hh signal transduction [137,141,142]. In the same studies, 
HSPGs could facilitate Hh ligand presentation to responding cells, concentrate 
Hh ligand in membrane microdomains proximal to Ptc, or may participate as 
part of a larger receptor complex. Despite different experimental models 
applied (animal versus cell culture), the data suggest that both the core protein 
and GAG chains contribute to reception and transduction of the Hh signal 
[138,139]. 3) Deficiency in the HSPG called perlecan leads to a microcephaly 
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in the mouse because of a decrease in cell proliferation in the medial 
ganglionic eminence likely related to insufficient Shh signalling [143]. 4) 
Mutation of Hh basic residues responsible for binding HS reduces the 
magnitude of Hh-induced proliferation of granule cells in culture [144], 
indicating that HS can act in conjunction with its core protein for stabilising or 
even specifying ligand-receptor complex formation.  
 
To sum up, HSPGs seem to facilitate the efficiency of the Hh/Shh signalling 
cascade in Drosophila and vertebrate systems at various levels, including 
secreting, retaining and stabilising ligands, and also providing accurate 
trafficking and appropriate targeting to ligand-receiving cells, though this model 
is still unclear in human. 
 
Cooperation between HSPGs and lipid moieties of Hh. Although the dual 
lipidation of Hh improves membrane affinity, other factors such as HSPGs also 
are required to contribute to cell surface association. More recently, it seems 
that only lipid-modified Hh could form into a polymeric complex [145,146] (Fig. 
1-4) to enhance its solubility for long-range transportation. An in vivo study 
[146] also shows that HSPGs are required for multimers formation and might 
be linked to Hh by Shifted, a secreted Wnt Inhibitory Factor homologue. Using 
Hh immunostaining and verified by immunoprecipitation, Nicole Gorfinkiel and 
colleagues observed that extracellular Yellow Fluorescent protein 
(YFP)-Shifted colocalised with Hh at ECM and further suggested that Hh might 
stabilise Shifted. Also, generated ttv clones in a shf2 or shfEY03173 background 
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leads to the suggestion that Shifted is required for the stabilisation of Hh by the 
HSPGs [146]. In addition, it is indicated that lipid modifications of Hh are not 
only essential for Hh/HSPGs interaction [145,146] but also critical for proper 
Ptc receptor anchoring. To sum up, the ability of lipid-modified Hhs to interact 
with HSPGs could influence Hh signalling and spreading efficiency through 
ECM. As for lipid-unmodified Hh, however, it has great difficulty to be retained 
and is poorly stabilised by the ECM and tends to diffuse freely [145,146]. 
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(from Mol. Mem, Biol. 2009. 26(1-2): 104-113) 
 
Figure 1-4. Model of active soluble Hh/Shh multimeric complex transport. 
After post-translational modifications in Hh-producing cells, Hh-Np proteins are 
secreted to extracellular matrix and form a multimeric complex with HSPGs. In 
Hh-receiving cells, the receptor Ptc is repressed by Hh and this releases Smo 
to activate the downstream signalling. The presence of HSPGs can improve 
the solubility of Hh proteins during trafficking in extracellular matrix and 
enhance Hh-Ptc interaction on Hh-receiving cells as well, and therefore 
promote subsequent signalling activity. 
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1-3.  Palmitoylation of Hh proteins in Hh signalling 
1-3-1. Protein lipid modifications 
Lipid modifications. Proteins are covalently modified with a variety of lipids, 
such as fatty acids, isoprenoids, GPI anchors, phosphatidylethanolamine (PE, 
in autophagy) and cholesterol. Lipid modifications can be divided into two 
groups based on their functional destinations - cytoplasmically oriented and 
extracellularly oriented. The former contains S-acylation (also named as 
thioacylation or palmitoylation), myristoylation, PE modification and prenylation 
(farnesylation and geranylgeranylation), while the latter includes GPI 
anchoring, cholesteroylation and some kinds of fatty acylation, such as of Hh 
proteins described herein [148]. Unlike myristoylation and farnesylation, 
palmitoylation alone can just provide sufficient hydrophobicity to stably anchor 
proteins to a lipid bilayer. N-myristoylation is the covalent addition of the fatty 
acid myristate to an N-terminal glycine residue via an amide linkage [149]. 
Prenylation is the addition of an isoprenoid (either a C15 farnesyl or a C20 
geranylgeranyl group) to a C-terminal cysteine residue via a thioether linkage 
[150]. Lastly, palmitoylation is the covalent addition of long-chain fatty acids, 
usually to a cysteine residue via a thioester linkage [151-153]. On the other 
hand, the best-characterised lipid modification that occurs in the lumen of the 
secretory pathway is the attachment of GPI anchors [154]. This lipid 
modification is composed of a phosphatidylinositol connected through a 
carbohydrate linker to the protein. After the GPI moiety is added in the ER, the 
protein traffics through the secretory pathway and finally targets to the cell 
surface, where the GPI anchor embeds the protein to the extracellular face of 
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the plasma membrane.  
 
The roles of protein lipidations are diverse, including the localisation and 
function of proteins. Among lipidations, the field of palmitoylation has 
advanced, in which the most common understanding for its function is to 
increase the affinity of a soluble protein to membranes, which can thereby 
regulate the protein localisation and function. Another function of 
palmitoylation is to regulate protein trafficking; the mechanism has been 
illustrated intensively for palmitoylated forms of the small GTPase Ras 
[152,153,155]. The third function for palmitoylation is to modulate protein 
stability; e.g. the yeast chitin synthase Chs3, a protein with six to eight 
transmembrane domains (TMDs). When palmitoylation is blocked, Chs3 
aggregates and is retained in the ER, indicating palmitoylation plays an 
important role in a quality control mechanism for a multimembrane-spanning 
protein [156]. The other way for palmitoylation to adjust protein stability is by 
regulating protein degradation; for example, palmitoylation of the yeast 
sphingoid long-chain base kinase Lcb4, a soluble protein palmitoylated at two 
internal cysteine residues. Under normal conditions, Lcb4 is downregulated 
upon entry of the cells into stationary phase. On the contrary, when 
palmitoylation of Lcb4 is blocked by mutation this does not occur. Thus, this 
indicates that the half-life of the Lcb4 protein is negatively regulated by 
palmitoylation in normal conditions [157]. Lastly, recent studies demonstrate 
that lipid modifications can facilitate the efficiency and specificity of signalling 
through not only correctly guiding a signalling molecule to its target within the 
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cell but also membrane-anchoring at specific cell surface microdomains/lipid 
rafts [158]. For instance, the particular dual lipid modification of Hhs can 
influence the distribution and activity of Hh signalling proteins. 
 
 
1-3-2. Multiple roles for protein lipidation in the Hh signalling 
pathway 
The study of the N-terminal palmitoylation of Hhs. N-terminal 
palmitoylation of Hh is facilitated by the product (Hhat) of the Hedgehog 
acyltransferase gene (also sightless, central missing or raspberry). This 
putative transmembrane acyltransferase is classified as a member of the 
palmitoyl acyltransferases (PATs) for yeast and mammalian proteins [14]. Hhs 
are unusual in being dually lipid-modified to be fully active [159]. Moreover, it 
has been shown that dual lipidation is critical not only for the interactions 
between Hh and Ptc but also for forming a suitable complex of Hh with HSPGs 
to target at the Hh-receiving cell [146]. On the contrary, lipid-unmodified Hh 
would be released from the cell into the extracellular fluid instead of remaining 
in the ECM. This extracellular transmission could promote the activation of 
low-threshold target genes far from Hh-producing cells [145]. It is now 
appreciated that Ptc might be located in lipid rafts/microdomains which 
contains specific sets of proteins including GPI-anchored proteins, doubly 
acylated proteins such as Src family kinases, palmitate- and cholesterol-linked 
proteins [160]. Hence, the interactions between particular HSPGs, Hh and Ptc 
are significant to Hh spreading through the epithelium surface, as well as Hh 
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signal transduction.  
 
Blocking Hhat enzymatic activity prevents formation of active palmitoylated 
Hhs and downregulates the Hh pathway in tumour cells which depend on 
active Hhs for their proliferation [161]. In the same study, the authors also 
confirmed the observation made previously by others that Hhat is localised in 
intracellular membranes of the secretory pathway, ER and/or Golgi. In cells, 
Pal-CoA is not free in the cytoplasm but is bound to ACBP (Section 1-1-3 and 
4-1) and therefore may require a transporter that facilitates its entry into the 
lumen of the secretory pathway where palmitoylation of Hhs presumably 
occurs [162]. Another mechanism suggested by Resh [12] is that the ER lumen 
is a likely source of Pal-CoA for palmitoylation of Shh because free fatty acids 
can be specifically transported into the ER lumen, where they are converted by 
luminal acyltransferases into Pal-CoA. 
 
Studies using Drosophila Hh variants showed that palmitoylation of Hhs is 
essential for effective production of the Hh signal and patterning in both wing 
imaginal discs and in embryos. Also, it is suggested that neither solely 
cholesterol modification nor N-terminal acylation of Hhs are adequate for their 
stable membrane localisation [7,163]. Genetic knockdown of the activity of 
Hhat by RNAi causes a reduction in overall Hedgehog protein hydrophobicity, 
as compared to the fully modified species, to a level that matches that of the 
unacylated version [31], again confirming previous propositions that the Hhat 
gene product is responsible for the N-terminal palmitoylation of Shh. 
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Consistent with the above observation, knockout mice deficient in Hhat are 
neonatal lethals and show defects in the developing neural tube and limbs 
similar to loss of palmitoylated Shh [164]. In the same study, overexpression of 
an unacylated Shh mutant (ShhC25S) in transgenic mice caused reduced 
activity in inducing Shh responses, and Shh protein lacking both types of lipid 
modification (ShhNC25S) had lower levels of residual activity. 
 
These results support the conclusion that Hh lipidation might enable Hh to form 
this complex to ensure targeting to the receiving cell for efficient signalling, 
combined with the fact that Ptc might be located in lipid rafts/microdomains 
which provide platforms for signal transduction and intracellular sorting. 
Although this acylation, thus far, has been reconstituted in vitro and proved to 
be an enzymatic mechanism, it does not exclude the possibility that this 
putative acyltransferase can also act as a chaperone-like transporter in vivo. 
 
The study of the C-terminal cholesteroylation of Hhs. The cholesterol 
moiety of Hh has been shown to associate tightly with the cell membrane [165] 
and is needed for Hh to be released from its producing cell under normal 
circumstances. The 12-pass transmembrane protein, Disp, is involved in this 
mechanism [13], as it is required only for the release of cholesterol-modified 
Hh. Thus, the cholesterol moiety of Hh is necessarily coupled to Disp to 
function for the proper release of Hh. Compared to fully modified Hh, a 
cholesterol-deficient form of Hh (HhN) has less potency to activate the Hh 
cascade. Moreover, HhC85S, a Drosophila variant that lacks palmitate due to 
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mutation of the acylation site, is much less potent than HhN [141] indicating 
that the palmitoyl adduct may play a more essential role in Hh signalling than 
cholesteroylation. In this study, it was also suggested that acylation plays a 
major role in guiding modified Hh proteins to specific membrane domains. 
 
One model provided by Guerrero and Chiang [166] is that the cholesterol 
moiety increases the local concentration of Shh as well as avoiding 
unregulated Shh spreading and dilution. Fractionation studies of secreted 
Hh/Shh proteins from the supernatant of Hh/Shh-expressing cells showed that 
lipid-modified Hh/Shh participates in high molecular weight structures as 
multimeric complexes, in which cholesterol seems to mediate association 
[141,167,168,169,170]. Since the lipid moieties are thought to be in the core of 
these complexes, analogous to micelles, multimerisation of Hh/Shh might 
concentrate Hh/Shh locally. It has also been suggested that lipoprotein 
particles carry lipid-modified Hh from the cell surface, acting as vehicles for 
long-range transport [171]. Cholesterol might stabilise these core complexes to 
interact with the ECM. To sum up, the data thus far suggest that the 
mechanisms of Hh secretion and spreading are generally conserved 
throughout evolution from Drosophila to vertebrates, despite some functional 
divergences in the Hh-receiving cells. Cholesterol modification of Hh is 
believed essentially to play a role in restrained dilution and regulated 
spreading of the morphogen through the extracellular environment. 
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1-4.  Hypothesis and aims 
1-4-1. The role of HSPGs in Shh signalling 
To date, Hh signal molecules are known to act as major mediators in many 
developmental processes and essentially require HSPGs for their proper 
distribution and signalling activity [172]. In addition, both the HSPG core 
proteins and their attached HS GAG chains are involved in this regulation 
[173,174]. Based on developmental and biochemical studies in Drosophila and 
vertebrate systems there are several conjectural mechanisms for how HSPGs 
could promote Hh signalling. On one hand, both Shh and Hh are secreted from 
cells as both monomeric and multimeric forms [164,175]. Soluble Hh 
multimeric complexes with HSPGs are freely diffusive and can improve Hh 
activity on target genes. On the other hand, the interaction between HSPGs 
and growth factors (GFs) could influence both GFs extracellular distribution 
and their ability to signal [126], e.g. perlecan by directly binding to Shh as a 
co-receptor can affect Shh signalling [176]. Furthermore, studies imply that 
HSPGs might participate in promoting cell surface microdomains/lipid rafts in 
which the plasma membrane organise into functional domains via dynamic 
clustering of sphingolipids and cholesterol [177]. In summary, HSPGs seem to 
facilitate the efficiency of these signalling cascades at various levels, including 
secreting, retaining and stabilising ligands, also providing accurate trafficking 
and appropriate targeting to ligand-receiving cells. 
 
Studies about Shh-HSPG interactions.  
In this work, I investigate the interaction between human (h) Shh and HSPGs 
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and clarify the biological function of hShh/HSPGs complexes in hShh 
signalling. The main aims are: 
 
• To determine whether hShh-N (recombinant, commercial) binds to 
heparin-Sepharose (as a model of HSPG interaction), evaluate the 
interaction efficiency, and verify the interaction by a competitive binding 
test. 
• If hShh-heparin binding is detected, establish an expression/purification 
system for wild-type and mutated hShh proteins in vitro via the 
pET-GST bacterial expression system containing mutate putative hShh 
residues involved in heparin binding to determine the key residues 
(based on modelling of Shh-heparin interaction by Dr. Barbara Mulloy, 
NIBSC, personal communication). 
• To test biological function of purified wild-type and mutated hShhs in 
C3H10T1/2 cells by determining alkaline phosphatase (AP) activity. 
• To test the signalling efficacy of mutated recombinant hShhs that cannot 
interact with HSPGs in PANC1 cells via both Semi-quantitative RT-PCR 
and immunoblot analyses for the induction of Ptc and Gli1 mRNA and 
with Ptc/Gli1 antibodies respectively. 
• To clarify the role of mutated hShhs that cannot interact with HSPGs in 
PANC1 cells proliferation and invasion. 
• To characterise the role of mutated hShhs in Shh multimeric complex 
formation using Shh RNAi knockdown, followed by overexpression of 
wild-type and mutant Shhs, gel-filtration chromatography and Shh 
immunoblotting. 
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1-4-2. The role of hHhat in Shh signalling 
To date, it has not been proved whether the palmitoylation of Shh proteins 
caused by endogenous Hhat occurs within the lumen of the ER, the Golgi, or 
both. Also, palmitoylation could occur during biosynthetic transit or at the 
plasma membrane. On the other hand, studies for functional roles of hShh 
palmitoylation and its interactions with HSPGs will provide a firm basis for 
understanding Shh lipidation in active Shh signalling, which provides 
proof-of-principle for targeting these aspects of hShh biology in tumour cell 
therapeutics, specifically in the pancreatic carcinoma context. 
 
Studies about Hhat in human Shh lipidation. 
The purpose of this part of my project is: 
1) To identify the intracellular localisation of endogenous hHhat in mammalian 
cells. 
2) To illuminate the biological function of palmitoylation of hShh in production of 
active hShh and in the formation of hShh multimeric complex. Specific aims: 
• To characterise an anti-peptide antiserum against hHhat prepared in the 
lab and use it to determine the intracellular localisation of Hhat by 
subcellular fractionation/Western blotting and immunofluorescence 
microscopy. 
• To establish and optimise RNAi knockdown of hHhat and test the effect 
on production of active palmitoylated Shh in PANC1 cells, using 
induction of Shh targets as a readout. 
• To clarify the role of hHhat in PANC1 cells proliferation and invasion. 
• To characterise the role of palmitoylation of hShh in Shh multimeric 
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complex formation using hHhat RNAi knockdown, gel-filtration 
chromatography and Shh immunoblotting. 
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CHAPTER 2 
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2. Materials and Methods 
 
2-1.  Cell culture 
Due to the poor in prognosis, rare in complete remission, and low survival rate 
(with fewer than 5%) of those diagnosed still alive five years after diagnosis, 
pancreatic cancer is a formidable disease to diagnose and treat [223]. About 
95% of exocrine pancreatic cancers are adenocarcinomas, the remaining 5% 
include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid 
carcinomas, colloid carcinomas, undifferentiated carcinomas, and 
undifferentiated carcinomas with osteoclast-like giant cells [223]. Hh signalling 
has a major role in the initiation and growth of pancreatic cancer [103-106]. In 
this study human pancreatic ductal adenocarcinoma (PDAC) PANC1 cell line 
was used as a model system. PDAC PANC1 cells (ATCC, CRL-1469) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 8% fetal bovine serum.  Human embryonic kidney 293a (HEK293a) line 
was generously provided by Dr. Birgit Leitinger and maintained in DMEM 
supplemented with 8% fetal bovine serum. Due to the fact that HEK 293 cells 
are very easy to grow and transfect very efficiently, in this study the cells were 
subjected to S100/P100 fractionation and immunoblotting for the hHhat 
antibody characterisation purpose (Section 4-2-2).  C3H10T1/2 fibroblasts 
generously provided by Dr. Kay Grobe were maintained in DMEM 
supplemented with 8% fetal bovine serum.  
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2-2.  General cloning techniques 
2-2-1.   Cloning of human ShhNs-pET41a(+) 
Human Shh cDNA clone was purchased from the I.M.A.G.E. Consortium 
(Accession No: BC111925, Clone ID: 40080739).  To express and purify 
active Shh from Escherichia coli, pET41a(+)-ShhNC24II was constructed.  At 
first, mutations were introduced into Shh by site-directed mutagenesis using 
the QuickChange Kit (Stratagene) to change Cys24 to Ile-Ile and add a stop 
codon after Gly197 from the I.M.A.G.E. clone.  Then, ShhNC24II cDNA was 
cloned into the pET-41a(+) expression vector at the PshAI and SacI sites to 
form pET41a(+)-ShhNC24II. I next generated pET41a(+)-ShhNC24II/K37.38S, 
pET41a(+)-ShhNC24II/K178S, pET41a(+)-ShhNC24II/K37.38.178S and 
pET41a(+)-ShhNC24II/K74S by site-directed mutagenesis.  PCR primers are 
self-designed using Oligonucleotide Properties Calculator and Primer X shown 
in Table 2-1.  E. coli DH5α and XL1 blue were used as competent cells for 
general cloning.  All restriction enzymes were purchased from NEB and all 
PCR products were sequence-verified. 
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Table 2-1. PCR primers for pET41a(+)-ShhNC24II constructs 
Primer Sequence (5' to 3' direction) 
C24II For GTATGCTCGGGACTGGCGATCATCGGACCGGGCAGGGGGTTC 
C24II Rev GAACCCCCTGCCCGGTCCGATGATCGCCAGTCCCGAGCATAC 
C198X For CAAATCGGGAGGCTGATTCCCGGGCTCGGC 
C198X Rev GCCGAGCCCGGGAATCAGCCTCCCGATTTG 
KK37/38SS For GAAGAGGAGGCACCCCAGTTCCCTGACCCCTTTAGCCTAC 
KK37/38SS Rev GTAGGCTAAAGGGGTCAGGGAACTGGGGTGCCTCCTCTTC 
K178S For GTACTACGAGTCCAGCGCACATATCCACTGC 
K178S Rev GCAGTGGATATGTGCGCTGGACTCGTAGTAC 
K74S For GAAACTCCGAGCGATTTAGCGAACTCACCCCCAATTAC 
K74S Rev GTAATTGGGGGTGAGTTCGCTAAATCGCTCGGAGTTTC 
PshAI-Shh-SacI For GATCATCGGACCGGGCAGGGGG 
PshAI-Shh-SacI Rev CGAGCTCTCAGCCTCCCGATTTGGC 
 
 
2-2-2.  Cloning of human Shhs-pcDNA-DEST40 
To establish a mammalian overexpression system of fully-lipidated hShh in 
vitro, a pcDNA-DEST40-hShh expression vector was constructed using the 
Gateway cloning system (Invitrogen) based on recombination between an 
entry vector and a destination vector. pENTR223.1-hShh (DNAFORM, 
provided by B Jovanović) was propagated in E. coli using spectinomycin (100 
µg/mL) for selection while. pcDNA-DEST40 (Invitrogen) was selected byusing 
chloramphenicol (30 µg/mL) and thefor selection. pcDNA-DEST40-hShh 
construct by was using ampicillin (100 µg/mL).  Then, 
pcDNA-DEST40-hShhK37.38S, pcDNA-DEST40-hShhK178S, 
pcDNA-DEST40-hShhK37.38.178S and pcDNA-DEST40-hShhK74S were 
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made using site-directed mutagenesis with primers in Table 2-1.  After 
confirmation by sequencing and Western blot for Shh, the constructs were 
used for overexpression in PANC1 cells. 
 
 
 
2-2-3.  Cloning of recombinant human Hhat-pEGFP-N3 
Human Hhat cDNA (Accession No: BC117130) was cloned into pEGFP-N3 
mammalian expression vector at the XhoI and BamHI sites, and the mouse 
Gup1 cDNA (kindly provided by Yoichiro Abe) was cloned into the same vector 
at the same sites.  The primers used in PCR are shown in Table 2-2. 
 
 
Table 2-2. PCR primers for pEGFP-N3-hHhat constructs 
Primer Sequence (5' to 3' direction) 
Hhat-pEGFP-N3 For GCTCGAGATGCTGCCCCGATGGG 
Hhat-pEGFP-N3 Rev CGGATCCGTCCGTGGCGTAGGTC 
 
 
2-3.  Expression and purification of recombinant 
human ShhNs in Escherichia coli 
The following induction and extraction protocol is based on the GE Healthcare 
directory.  Overnight growing bacterial cultures of GST-ShhNC24II clones 
were diluted 1:100 into fresh pre-warmed 2xYTA medium (Tryptone 16 g/l, 
Yeast extract 10 g/l, NaCl 5 g/l, pH7.0), distributed into appropriate flasks and 
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grown at 37°C with shaking until the A 600 reached 0.6.  Then, 100 mM IPTG 
(isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 
0.1 mM and incubation continued overnight at 20°C. IPTG was used as a 
molecular mimic of allolactose, a lactose metabolite that triggers transcription 
of the lac operon.  Cells were harvested (4,000 ×  g, 30 min) and completely 
suspended in 50 µl of ice-cold 1X PBS (150 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) per ml of culture.  Cell lysis was done by 
adding 0.2% lysozyme for 30 min on ice followed by sonication (15,000, 10 sec 
X4, on ice) and adding 20% Triton X-100 to a final concentration of 1%.  The 
resulting extract was centrifuged (11,000 ×  g, 40 min, at 4°C) to remove the 
cellular debris.  After that, the GST-ShhC24II fusion protein was purified in a 
three-step procedure as described below (shown in Fig. 2-1). 
 
Firstly, 2 ml of a 50% slurry of Glutathione-Sepharose 4B (GE Healthcare) 
equilibrated with 1X PBS were added to each 100 ml of bacterial sonicate.  To 
test Glutathione-Sepharose binding efficiency, the lysates were incubated with 
gentle agitation at room temperature for 30 min, 2hr and 4hr and at 4°C for 
overnight.  The Glutathione-Sepharose 4B pellet was washed with 10 column 
volumes (CVs) of 1X PBS for a total of three washes.  1 U recombinant 
Enterokinase (rEK) was subsequently added to the Glutathione-Sepharose 4B 
pellet directly to release ShhNC24II proteins from the slurry by cleavage of the 
enterokinase recognition site encoded in the vector.  Incubation was done 
with gentle agitation at room temperature for 2hr and 4hr and at 4°C or 
overnight to test rEK efficiency.  Lastly, residual rEK was removed by using 
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EKapture Agarose beads to harvest the ~19kDa soluble ShhNC24II proteins.  
The rEK kit (S•Tag™ Purification Kit) was purchased from Novagen. 
 
 
Figure 2-1. Diagram of the hShh-GST™™ ™™  protein purification system 
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2-4.  Transfection and over-expression of cDNA in 
mammalian cells 
2-4-1.  Human Shhs-pcDNA-DEST40 constructs 
To establish a mammalian overexpression system of fully-lipidated hShh in 
vitro, I constructed and transfected/expressed pcDNA-DEST40-hShh vector in 
PANC1 cells.  The cloning details are described in Section 2-2-2. 
 
For the Shh oligomerisation assay, siRNA and plasmid co-transfections were 
carried out sequentially in PANC1 cells (described in Section 2-14-1).  
Transfections of mammalian expression vectors were carried out using 
Lipofectamine 2000 (Invitrogen).  One day before transfection, PANC1 cells 
were plated in 2 ml of growth medium in 6-well plates without antibiotics such 
that they were ~50% confluent at the time of transfection.  For each 
transfection sample, 2.5 µg DNA were diluted in 500 μ l medium without 
serum.  After gently mixing, 2.5 µl Plus reagent were added followed by 
incubation for 5 min at room temperature.  Then 5 µl Lipofectamine 2000 
were added to the mixture and incubated at room temperature for 30 min.  
The DNA-Lipofectamine 2000 complexes were added to each well containing 
cells and medium, and mixed gently.  After incubation at 37 ° C in a CO2 
incubator for 48hr, the cells were ready for further analysis. 
 
2-4-2.  Human Hhat-EGFP and mouse Gup1-EGFP constructs 
Transfections of mammalian expression vectors were carried out using 
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Lipofectamine 2000 (Invitrogen).  24hr before transfection, 1X105 cells were 
plated per well in 2 ml of the appropriate culture medium without antibiotics.  
For each well of cells, 2.5 µg of DNA were diluted into 500 µl medium without 
serum in wells of a 6-well plate.  For each well of cells, 2.5 µl of Plus reagent 
were added to the DNA-medium mixture and incubated for 5 min at room 
temperature.  Then, 5 µl of the Lipofectamine 2000 were added to each well 
containing diluted DNA, mixed gently, and incubated at room temperature for 
30 min to allow DNA-Lipofectamine 2000 complexes to form.  Lastly, the 
DNA-Lipofectamine 2000 mixture was transferred to the cultured cells.  48hr 
after transfection, the cells were harvested for further analysis. 
 
2-5.  RNAi knockdown 
2-5-1.  Human Sonic hedgehog (Shh) knockdown 
hShh knockdown (KD) assay was carried out in PANC1 cells.  To examine KD 
efficacy, immunoblotting was carried out using rabbit polyclonal anti-Shh H-160 
on cells harvested at 24hr, 48hr and 72hr after siRNA transfection.  Human 
Shh siRNA oligomers (sc-29477) were ordered from Santa Cruz Biotechnology, 
Inc.  Negative controls that do not target any endogenous transcript are 
needed to control for non-specific effects on gene expression caused by 
introducing any siRNA.  In this experiment, the negative control was 
SilencerR FAMTM-Labelled Negative Control #1 siRNA (Ambion).  siRNA 
transfections were carried out with FuGENE 6 Transfection Reagent (Roche) 
by plating 0.3 million cells per well in a 6-well plate and 6hr later treating with 
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10 pmol siRNA oligomers and 3 µl FuGENE 6 Transfection Reagent. The 
signals from immunoblots were quantified using Scion Image software. 
 
 
2-5-2.  Human Hedgehog acyltransferase (hHhat) knockdown 
Human Hhat siRNA duplex oligomers (Table 2-3) were designed and ordered 
from MWG Biotech, US.  Mutated hHhat siRNA duplex oligomers (Table 2-3; 
Hhat-Mut) were from Invitrogen.  siRNA transfections were carried out by 
plating 0.3 million PANC1 cells per well in a 6-well plate and 6hr later treating 
with 20 pmol siRNA oligomers and 3 µl FuGENE 6 Transfection Reagent 
(Roche) per reaction.  To examine KD efficacy, immunoblotting was 
performed using rabbit polyclonal anti-Hhat on cells harvested at 24hr, 48hr 
and 72hr after siRNA transfection.  The negative control for this experiment 
was SilencerR FAMTM-Labelled Negative Control #1 siRNA (Ambion). The 
signals from immunoblots were quantified using Scion Image software. 
 
Table 2-3 Human Hhat siRNA oligomers 
siRNA oligomers Sequence (5' to 3' direction) 
Hhat UUAAUCAGGUAUGUGUACAUUCCAGUG 
Hhat-Mut UUAAUCAGGCAUAUGUACGUUCCAGUG 
 
 
2-6.  Semiquantitative reverse transcription — 
polymerase chain reaction (RT-PCR) 
2-6-1.  Human Shh proteins treatment of PANC1 cells 
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To determine the effects of different hShh proteins in Shh signalling in a 
human model system, I applied different purified proteins (1 µg/ml) to PANC1 
cells for 24hr; after treatment with ShhNC24II, ShhNC24II/K37.38S, 
ShhNC24II/K178S, ShhNC24II/K37.38.178S or ShhNC24II/K74S the PANC1 
cells were analysed by RT-PCR.  Total RNA extraction from cultured cells 
was done with Trizol according to the manufacture’s instruction (Invitrogen).  
PANC1 cells were lysed directly in a culture dish by adding 1 ml of Trizol 
reagent to a 3.5 cm diameter dish (the amount of Trizol reagent added is 
based on the area of the culture dish ~1 ml per 10 cm2), and passing the cell 
lysates several times through a pipette. To induce phase separation, I 
incubated the homogenised samples at 25
°
C for 5 min to permit the complete 
dissociation of nucleoprotein complexes.  Then, 0.2 ml of chloroform was 
added per 1 ml of Trizol reagent.  Microtubes were shaken vigorously by hand 
for 15 sec and incubated at 25
°
C for 2 to 3 min.  The samples were 
centrifuged at 12,000 ×  g for 15 min at 4 °C.  Following centrifugation, the 
mixture separates into a lower red phenol-chloroform phase, an interphase, 
and a colourless upper aqueous phase.  RNA remains exclusively in the 
aqueous phase (about 60% of the volume of Trizol reagent used for 
homogenisation).  After transferring the aqueous phase to a fresh microtube, 
the RNA from the aqueous phase was precipitated by mixing with isopropyl 
alcohol (0.5 ml per 1 ml of Trizol reagent used for the initial homogenisation) 
followed by incubating the samples at 25
°
C for 10 min and centrifugation at 
12,000 ×  g for another 10 min at 4 °C.  After centrifugation, the RNA 
precipitate forms a gel-like pellet on the side and bottom of the microtube.  To 
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wash the RNA, the supernatant was removed and the RNA pellet was washed 
with 75% ethanol (1 ml per 1 ml of Trizol reagent used for the initial 
homogenisation).  The sample was mixed by vortexing and centrifuged at 
7,500 ×  g for 5 min at 4 °C.  At the end of the procedure, the RNA pellet 
was briefly air-dried for 5-10 min, then dissolved in 100 µl RNase-free water - 
and incubated at 60
°
C for 10 min. There are three quality controls that are 
performed on isolated RNA. One is to determine the quantity of RNA that has 
been isolated, the second is the purity of RNA that has been isolated and the 
third is the integrity of the RNA that has been isolated. Isolated RNA was 
quantified using UV absorption using a NanoDrop spectrophotometer and the 
absorbance is measured at 260 and 280 nm. The concentration of nucleic acid 
can be determined using the Beer-Lambert law, which predicts a linear change 
in absorbance with concentration. RNA has its absorption maximum at 260 nm 
and the ratio of the absorbance at 260 and 280 nm is used to assess the RNA 
purity of an RNA preparation. Pure RNA has an A260/A280 of 2.1 and value of 
1.8-2.0 indicates that the isolated RNA is pure. After quality of isolated RNA 
was confirmed, the RNA was stored at -80
°
C ready for following reverse 
transcription. The integrity of isolated RNA was examined by agarous gels in 
Fig. 3-8A. 
 
cDNA was synthesised by random priming from 1 µg of total RNA with 
SuperScript II Reverse Transcriptase kit (Invitrogen), according to the 
manufacturer’s instructions.  200 ng random primers were added to 1µg of 
extracted RNA, 1 µl dNTP mix (10 mM each) and distilled water to final volume 
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of 13 µl in a nuclease-free microcentrifuge tube and incubated at 65
°
C for 5 
min.  After brief centrifugation, 4 µl 5X First-Strand Buffer and 2 µl 0.1 M DTT 
were added to each reaction and incubated at 25
°
C for 2 min.  Then, 1 µl 
(200 units) of SuperScript II RT was added to each reaction followed by 
incubating at 25
°
C for 10 min and then at 42
°
C for 50 min.  At the end of 
the protocol, the reaction was terminated by heating at 70
°
C for 15 min.  The 
samples were now ready for PCR analysis. 
 
The PCR primers and PCR conditions used are described in Table 2-5 
[224,225].  PCR was done with KOD Hot Start DNA Polymerase (Novagen) 
following the manufacturer’s instructions shown in Table 2-4.  Cycling 
conditions: 29-32 cycles of 30 sec at 95°C, 30 sec at 55-60°C, and 2 min/Kb at 
72°C.  PCR products were resolved by electrophoresi s on 1.7% agarose gels 
and visualised by ethidium bromide staining. The signals from RT-PCR were 
quantified using Scion Image software. 
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Table 2-4. PCR reaction setup 
 
 
 
Table 2-5. Primers used for RT-PCR 
 
 
 
  
71
2-6-2.  Human Hhat knockdown in PANC1 cells 
To determine the role of Hhat in Shh signalling in a human model system, I 
transfected hHhat siRNA into PANC1 cells.  48hr post-transfection, the cells 
were harvested and processed for RT-PCR to analyse pathway activity. RNA 
extraction, cDNA synthesis, PCR and product analysis were done as in 
Section 2-6-1. 
 
 
 
2-7.  Heparin binding assay 
2-7-1.  Benchtop elution method 
Heparin-Sepharose was purchased from Sigma (H6508).  5 µg of relevant 
Shh proteins (ShhNC24II, ShhNC24II/K37.38S, ShhNC24II/K178S, ShhN 
C24II/K37.38.178S or ShhNC24II/K74S) were applied at room temperature to 
a Heparin-Sepharose column equilibrated with 5-10 CVs of PBS.  Then, the 
column was washed with 10 CVs of this buffer and eluted with a step gradient 
of 0.15, 0.24, 0.33, 0.5 and 0.75 M NaCl by 1 CV for each fraction. Lastly, it 
was washed with 5 CVs 2 M NaCl.  Totally, over 20 CVs were run under 
gravity and each fraction was collected as 1 CV.  To verify this experiment a 
competitive binding assay was performed as follows.  10 µg hShh proteins 
were mixed with free Heparin (sodium salt, Sigma, final to 1mg/ml) at room 
temperature for 15 min.  Then this pre-incubated mixture was applied to 
Heparin-Sepharose following the procedures described above.  
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2-7-2.  ÄKTA Purifier system chromatography 
100 µg purified hShh proteins (ShhNC24II, ShhNC24II/K37.38S, 
ShhNC24II/K178S, ShhNC24II/K37.38.178S and ShhNC24II/K74S) in 100 µl 
phosphate buffer (described below) were applied to a Heparin affinity column 
(HiTrap Heparin HP, 0.7 x 2.5 cm; GE Healthcare) using an ÄKTA Purifier 
system (Pharmacia LKB).  Elution was with a linear gradient started with 10 
CVs 0 M NaCl wash, followed by 10 CVs 0-0.7 M NaCl elution, and ended with 
5 CVs 0.7 M NaCl elution in 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM 
KH2PO4 (phosphate buffer, pH 7.4).  As a positive control, the HepII domain 
of fibronectin was kindly provided by Dr. Atsuko Yoneda (University of 
Copenhagen) [180]. 
 
2-8.  Differentiation of C3H10T1/2 osteoblast 
precursor cells/alkaline phosphatase (AP) assay 
1 X 105 C3H10T1/2 cells were plated per well in 6-well plates.  Purified 
hShhNC24II proteins were added to the culture medium the day after plating at 
a concentration of 10, 100, 300, 500, 1000 and 2000 ng/ml.  To some 
samples, Shh inhibitory antibody 5E1 (10 µg/ml) was added together with 
hShh proteins.  5 days post-hShh proteins treatment, C3H10T1/2 cells were 
lysed (in 150 µl 1% Triton X-100 in PBS, pH 7.4 with protease inhibitors; 
complete protease inhibitor cocktail, Roche) and Shh activity was tested by 
measuring alkaline phosphatase (AP) induction in the cells at 405nm using a 
microplate reader (Bio-Rad Lumimark), accomplished by incubation with 150 
µl 120mM p-nitrophenol phosphate (Sigma), 50 mM MgCl2 and 1 M 
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diethanolamine, pH 10.4 (Sigma) at room temperature for 30 min.  Assays 
were performed in triplicate. 
 
2-9.  Human Hhat antibody generation 
In this study, in order to improve the chances of producing a successful 
antibodies pool, a strategy of multi-peptide co-immunisation was used in which 
more than one target peptides were chosen within the same protein 
sequences and use them as antigen in a co-immunisation protocol. Generally, 
having several epitopes derived from a single protein will mathematically 
increase the chances of obtaining a pool of antibodies that will recognise the 
target protein. Here, we used an anti-peptide approach to generate hHhat 
antibody based on two extramembrane sequences from hHhat as epitopes: 
KQMQQQEHDSLKASL (aa227 – aa241) and CYSHVGIAWAGTYATD 
(aa478 – aa493).  These sequences were chosen by Prof. Magee based on 
prior experience, using criteria of surface exposure, hydrophilicity and 
antigenic potential.  They were synthesised, coupled to KLH carrier and 
coimmunised into two rabbits by Severn Biotech Ltd., UK.  Antibodies were 
characterised against subcellular fractions by immunoblotting. 
 
2-10.  S100/P100 fractionation 
To obtain S100 (cytosol) and P100 (membrane) fractions, 0.6 million human 
HEK293a cells were swollen on ice for 10 min in 20 mM Tris, pH 7.5, 5 mM 
MgCl2, 1 mM EDTA, 250 mM sucrose, 0.1 mM DTT containing protease 
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inhibitors (complete protease inhibitor cocktail, Roche), then homogenised by 
passing the lysates through a 23-gauge (0.6 mm) needle attached to a sterile 
plastic syringe for 15 times and centrifuged at low speed to remove unbroken 
cells and nuclei.  The post-nuclear supernatants were centrifuged at 100,000 
X g for 30 min at 4°C in a Beckman TLA100 rotor to yield S100 (soluble 
cytoplasmic material after 100,000 X g centrifugation) and P100 (membranes 
pelleted by 100,000 X g centrifugation). 
 
2-11.  Click chemistry/cell-based palmitoylation using 
bioorthogonal tag 
The traditional method used for tracking protein lipid modification is based on 
radioisotopic labelling which is time-consuming, usually takes days, weeks or 
even months to process. As an alternative approach “click-chemistry” was 
used in this study. The term “click” was explained by Fokin to show that with 
the use of these methods -  “Joining molecular fragments is as easy as 
“clicking” together the two pieces of a buckle. When its two pieces can reach 
each other, the buckle works no matter what is attached to it, and the 
components of the buckle can make a connection only with each other.” [233] 
One of the most common catalyst systems for Cu(II)-catalysed azide-alkyne 
cycloaddition (CuAAC) uses a Cu(II) salts catalyst at room temperature in the 
presence of a reducing agent (sodium ascorbate or metallic copper often be 
used). Copper catalysts (Fig. 2-2) accelerate the reaction of azides with 
terminal alkynes by ~107 relative to the uncatalysed version, making it 
conveniently fast at room temperature [234]. Copper and ruthenium are the 
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commonly used catalysts in the reaction. The use of copper as a catalyst 
results in the formation of 1,4-regioisomer whereas ruthenium results in 
formation of the 1,5- regioisomer [235].  The CuAAC reaction with a broad 
range of functional groups and reaction conditions has made this process have 
been broadly used in many applications; e.g. in polymer chemistry, medical 
chemistry, bioconjugations, materials science, and synthetic chemistry 
[236-240]. In this study, the palmitate analogue heptadec-16-ynoic acid 
(YnC15) was used which metabolically incorporates into proteins and then 
detected by following reaction with an azido-TAMRA-biotin tag. 
 
 
 
 
 
Figure 2-2. Chemical transformation of Cu(II)-catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction. CuAAC, one of the most popular reactions 
within the click chemistry concept, demonstrated here used to address azides 
in biological systems. The reaction is very selective and efficient, but it requires 
addition of a copper catalyst. In 2006, Lipshutz and Taft found that copper 
supported on charcoal (Cu(II)/C) was an efficient catalyst [241].  
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48hr after siRNA transfection, the PANC1 culture medium was changed to 
DMEM labeling medium (1 mM sodium pyruvate and 100 µM palmitate 
analogue, heptadec-16-ynoic acid YnC15, provided by Dr. Ed Tate, Chemistry 
Department, Imperial College) for 36hr.  PANC1 cells were washed in PBS, 
and cell extracts were prepared in lysis buffer (1% Triton X-100 and protease 
inhibitors (complete protease inhibitor cocktail, Roche) in PBS, pH 7.4).  Cell 
lysates and medium were immunoprecipitated for Shh separately using 5E1 
anti-Shh MAb (Developmental Studies Hybridoma Bank, USA).  Azide-alkyne 
cycloaddition (click chemistry [181,182]) was carried out directly on protein 
G-agarose beads using azido-TAMRA-biotin capture reagent.  In vitro 
palmitoylation was detected by fluorescence imaging.  Protein concentrations 
were measured using Bio-Rad Protein Assay Reagent (Bio-Rad, Richmond, 
CA, USA) following the manufacturer’s suggested procedure. A standard curve 
for protein concentration was created here using known concentrations of 
bovine serum albumin (BSA) (Fig. 2-3). 
 
 
 
 
 
 
 
Figure 2-3. A protein standard calibration curve. Standard curve generated 
with BSA in water, showing concentration from 0-1.4 mg/ml. Data points are 
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averages for triplicates.    
 
2-12.  Western blotting 
2-12-1.  Human Shh proteins treatment of PANC1 cells 
4hr after plating PANC1 cells (3 X 105 cells per well in a 6-well plate), 1 µg/ml 
purified hShh proteins (ShhNC24II, ShhNC24II/K37.38S, ShhNC24II/K178S, 
ShhN C24II/K37.38.178S or ShhNC24II/K74S) with or without 5E1 (10 µg/ml) 
were added to the cultured medium.  48hr later, cells were harvested and 
analysed by Western blotting. 
 
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
0.3 million cells were harvested and lysed by the addition of loading buffer (45 
mM Tris (pH 6.8), 10% glycerol, 1% SDS, 20 mM DTT, 0.01% bromophenol 
blue) to the cell, followed by treatment with 20-30 passages through a syringe 
using a 23-gauge (0.6 mm) needle.  After electrophoresis, proteins were 
transferred using a semi-dry transfer unit (AAHoefere, TE77X Semidry Blotter, 
USA) with 5 mA/cm2 for 1hr at room temperature to nitrocellulose membranes 
(Millipore, Bedford, MA, USA), blocked at room temperature for 1hr in PBS 
with 5% skim milk, and then incubated with primary antibody diluted in PBS 
with 5% skim milk for 16hr at 4°C.  Table 2-6 shows  antibodies used in 
Western blotting. 
 
Goat polyclonal anti-Patched (ab51983) and mouse monoclonal α-Tubulin 
(DM1A, ab49928) were purchased from Abcam.  Rabbit polyclonal anti-GLI-1 
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(H-300, sc-20687) was purchased from Santa Cruz Biotechnology.  
Secondary antibodies were horseradish peroxidase (HRP)-conjugated goat 
anti-mouse immunoglobulin IgG1, HRP-conjugated goat anti-rabbit IgG, and 
HRP-conjugated donkey anti-goat IgG (all used at 1:20,000; Southern Biotech).  
Bound immunocomplexes were detected using enhanced chemiluminescence 
detection reagents (Pierce) and were visualised by exposing the membrane to 
x-ray film (Fuji medical x-ray film, Super RX, 11860).  The signals from 
immunoblots were quantified using Scion Image software. 
 
 
 
Table 2-6. Antibodies used for immunoblotting analysis  
 
 
 
2-12-2.  Hhat knockdown in PANC1 cells 
For hHhat antibody characterisation, immunoblotting was carried out 24hr after 
transfection of HEK293 cells with appropriate expression vectors expressing 
hHhat-EGFP or mGup1-EGFP.  For hHhat knockdown, immunoblotting was 
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carried out 24hr, 48hr and 72hr after siRNA transfection.   
 
2-13.  Immunofluorescence staining and confocal 
microscopy 
PANC1 cells were seeded onto glass coverslips in 6-well plates at a density of 
1X105 cells/well and transfected with hHhat-EGFP.  48hr after transfection, 
the cells were fixed with 4% formaldehyde freshly prepared in PBS at 25°C for 
10 min and imaging was performed using a Zeiss LSM510 laser-scanning 
confocal microscope in the FILM imaging facility.   Endogenous hHhat, Golgi 
complex and endoplasmic reticulum (ER) were visualised after staining with 
rabbit polyclonal anti-Hhat IgG (1:100, described above), mouse monoclonal 
anti-GM130 IgG1 (1:600, BD Transduction Laboratories™) and mouse 
monoclonal anti-protein disulfide isomerase (PDI) IgG1 (1:100, BD 
Transduction Laboratories™) respectively, followed by Alexa-conjugated 
secondary antibodies (Hhat with anti-rabbit Alexa488; GM130 and PDI with 
anti-mouse Alexa568). 
 
2-14.  Shh oligomerisation assay 
2-14-1. Co-transfection of human Shh siRNA and 
pcDNA-DEST40-hShh plasmids in PANC1 cells 
In this Shh oligomerisation assay, siRNA and plasmid co-transfection were 
carried out sequentially in PANC1 cells.  I set out by plating PANC1 at 1 x 10
5 
cells/well in a 6-well format (2 ml medium, no antibiotics).  After cell 
attachment, cells were treated with 10 pmol of Shh siRNA following the 
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standard FUGENE 6 transfection protocol (described in Section 2-5-1) to 
knock down endogenous wild type Shh.  16hr later, pcDNA-DEST40-hShh 
expression vectors were transfected into the cell. The plasmid transfection 
protocol was described in Section 2-4-1.  72hr after the siRNA transfection, 
culture medium was changed to SFM for 24hr.  Then, conditioned media were 
collected and centrifuged at 14,000 X g for 10 min.  The culture media were 
analysed by gel filtration performed by fast protein liquid chromatography 
(ÄKTA Protein Purifier, Amersham Biosciences) using a Superdex200 10/300 
GL column (Amersham Biosciences) equilibrated with phosphate buffer (PB; 
2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 7.4) at 4° C.  Elution 
was carried out in PB.  The molecular mass standards Blue dextran, 2000 
kDa; Apoferritin, 480 kDa; Alcohol dehydrogenase, 150 kDa; Albumin, 67 kDa 
and recombinant Human ShhN (C24II) (R&D Systems, Inc.), 19 kDa were 
used to calibrate the column.  Eluted fractions (1 ml) were collected and were 
trichloroacetic acid (TCA)-precipitated (see Section 2-14-3), then examined by 
Shh dot blotting with antibody H-160.  The signals from dot blots were 
quantified using Scion Image software. 
 
 
2-14-2.  Human Hhat KD in PANC1 cells 
72hr after hHhat siRNA transfection, culture medium was changed to SFM for 
24hr.  Gel filtration analysis of clarified conditioned SFM was performed as 
above.  The signals from dot blots were quantified using Scion Image 
software. 
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2-14-3.  Trichloroacetic acid (TCA) precipitation 
Trichloroacetic acid (TCA, also known as trichloroethanoic acid) is widely used 
in biochemistry for the precipitation of macromolecules such as proteins, DNA 
and RNA.  The TCA precipitation protocol was as follows.  Firstly, mix 150 µl 
100% (w/v) TCA with 1.5 ml cell culture medium and incubate on ice for 30 min.  
After centrufuging at 14,000 X g, 4° C for 20 min, the pellet was washed with 1 
ml 100% ice-cold acidic acetone.  Repeat the centrifugation step at 14,000 X 
g, 4° C for 15 min followed with air-drying for 5-10 min to remove acetone.  
Lastly, for SDS-PAGE add 2X or 4X sample buffer and boil sample for 10 min 
in 95°C heat block before loading sample onto polya crylamide gel. 
 
 
2-15.  PANC1 invasion assay 
2-15-1. Human Shh proteins treatment of PANC1 cells 
Biocoat Matrigel Invasion Chambers with 8 µm pores in 6-well plates (BD 
Biosciences) were used in invasion assays.  To determine the effect of 
mutated Shh proteins on PANC1 invasion ability, 72hr before PANC1 cells 
were plated to the chambers the cells were pretreated with hShh siRNA 
reagent (described in Section 2-2-1) together with exogenous recombinant 
Shh proteins (1 µg/ml). The reason why 72hr was chosen here is due to 
reduced Shh signalling in PANC1 cells caused by pre-treated with 1 µg/ml 
purified Shh proteins for 48hr (Fig. 3-8 D and E), and combined with the fact 
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that optimised hShh KD was observed on 72hr after siRNA transfection (Fig. 
2-4).  Shh proteins-containing media were changed every 48hr.  PANC1 
cells were detached with 5 mM EDTA in PBS, resuspended in serum-free 
DMEM and added to the upper compartment of the chamber (1 x 105 
cells/well).  Conditioned medium (8% FCS) was placed in the lower chambers.  
After 24hr of incubation at 37°C, the cells on the upper surface were 
completely removed by wiping with a cotton swab, and then the filter was fixed 
with 100% methanol and stained with crystal violet solution.  Cells that had 
migrated from the upper to the lower side of the filter were photographed and 
counted with an inverted microscope (10 fields/filter; ID 03 Carl Zeiss Ltd, 
Welwyn Garden City, UK). 
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Figure 2-4. hShh RNAi knockdown in PANC1 cells. To examine hShh RNAi 
KD efficacy in PANC1 cells, Western blots for Shh were processed after 24hr, 
48hr and 72hr siRNA transfection for both cell lysates (A) and medium (B). 
Tubulin was used a loading control. Shh-Scr (scrambled siRNA) was used as a 
negative control to specify Shh siRNA. In B, medium samples were TCA 
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precipitated then examined by Shh Western blots. The signals from 
immunoblots were quantified using Scion Image software. Correspondent 
quantitative results are shown below Western blots. 
 
 
 
2-15-2.  Human Hhat KD in PANC1 cells 
To determine the effect of hHhat KD on invasion, PANC1 cells were pretreated 
with Hhat siRNA (described above) for 72hr before they were added to the 
Matrigel Invasion chamber and invasion assessed as above. The reason why 
72hr was chosen here is due to optimised condition for reduced Shh signalling 
in PANC1 cells caused by Hhat KD was observed on 72hr after siRNA 
transfection (Fig. 4-8 C and D).  
 
2-16.  PANC1 proliferation assay and flow cytometry 
2-16-1. Human Shh proteins treatment of PANC1 cells 
Carboxyfluorescein succinimidyl ester (CFSE, Sigma, Cat. No. 21888), a 
fluorescent cell staining dye, was used in the PANC1 proliferation assay.  Due 
to the hydrolysis of CFSE by intracellular esterases, once CFSE incorporates 
into cells it is not transferred to adjacent cells.  Combined with the fact that 
CFSE will distribute to two daughter cells equally following each cell division, 
CFSE represents an extremely valuable fluorescent dye for proliferation study.  
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The detailed protocol was as follows.  Briefly, after 24hr of synchronisation in 
SFM, cells were treated with hShh siRNA together with purified hShh proteins 
(1 µg/ml each; hShhNC24II, hShhNC24II/K37.38S, hShhNC24II/K178S, 
hShhNC24II/K37.38.178S or hShhNC24II/K74S) or 5E1 (Day1 sample, 10 
µg/ml) separately, and then all samples were labeled with 2.5 µM CFSE at 37
℃
 for 15 min. Shh proteins-containing media were changed every 48hr.  
5E1-Day4 (10 µg/ml) treatment was carried out 72hr after synchronisation, to 
mimic siRNA KD kinetics in vivo.  After 8 days stimulation, cell division was 
indicated by decreased CFSE fluorescence intensity per cell, as analysed by 
flow cytometry.  For flow cytometer assessment, PANC1 cells were removed 
from plates with ice-cold FACS buffer (1% FCS and 2 mM EDTA in PBS) and 
resuspended in the same buffer.  Cells were analysed with a FACScalibur flow 
cytometer. 
 
2-16-2.  Human Hhat KD in PANC1 cells 
Briefly, after 24hr of synchronisation in SFM, cells were transfected with 
siRNAs (test and controls) or treated with anti-Shh 5E1 blocking antibody 
(Day1, 10 µg/ml) and then all conditions were labeled with 2.5 µM CFSE at 37
℃
 for 15 min.  For some wells, 5E1 treatment was carried out 72hr after 
synchronisation (Day4, 10 µg/ml), to mimic RNAi KD.  After 8 days of culture, 
cell division was indicated by decreased CFSE fluorescence intensity per cell, 
as analysed by flow cytometry as above. 
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2-17.  Statistical analysis 
All experiments were replicated at least three times, and statistical significance 
was measured by using the two-tailed t test. A P value of less than 0.01 was 
considered to indicate statistical significance.  The two-tailed test is a 
statistical test used in this study. This contrasts with a one-tailed test, in which 
only one of the rejection regions sufficiently small or sufficiently large is 
preselected according to the alternative hypothesis being selected, and the 
hypothesis is rejected only if the test statistic satisfies that criterion. Generally, 
if the distribution from which the samples are derived is considered to be 
normal, Gaussian, or bell-shaped, then the test is referred to as a one- or 
two-tailed T test. If the test were performed using the actual population mean 
and variance, rather than an estimate from a sample, it would be called a one- 
or two-tailed Z test.             
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3. The Role of HSPGs in Human Shh Signalling 
 
3-1.  Introduction 
Proteoglycans include secreted forms and cell-associated forms. Structurally, 
HSPGs consist of a core protein classified into three distinct classes - the 
Syndecans with a single transmembrane domain, the Glypicans with a GPI 
anchor and a varied group of secreted proteoglycans, based on their core 
protein structure - with one or more HS chains. Functionally, heparan sulfate 
proteoglycans (HSPGs) not only mediate significant interactions between cells 
and their environment but also regulate the distribution of extracellular 
signalling molecules such as morphogens through binding to them [183-186]. 
This great potential is based on HSPGs’ enormous structural differences - 
partly via the additional modifications in HS chains through the repeating 
disaccharide chain elongation and sulphation. 
 
To date, Hedgehog (Hh) / Sonic hedgehog (Shh) signal molecules are known 
to act as major mediators in many developmental process and essentially 
require HSPGs for their proper distribution and signalling activity [172]. 
Nevertheless, the mechanisms of their dependence in man are still unclear. In 
the case of Hh/Shh long-range signalling in Drosophila and mice, the activity is 
enhanced through forming a multimeric complex to increase Hh/Shh solubility, 
which is one critical criterion for protein stability [187]. Notably, this complex 
form demonstrates higher signalling efficiency than the monomer and the form 
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requires both the HSPG core proteins and their attached HS GAGs 
[173,174,187,188]. Based on previous studies, there are several conjectural 
mechanisms for how HSPGs promote this signalling, as follows. On the one 
hand, both Shh and Hh are secreted from cells as both monomeric and 
multimeric forms [164, 169]. This soluble Hh/Shh multimeric complex with 
specific HSPGs - Perlecan and Glypican - is freely diffusive and can regulate 
Shh signalling [176, 189]. On the other hand, the interaction between HSPGs 
and growth factors (GFs) could influence both GFs extracellular distribution 
and their ability to signal [190]; e.g. Perlecan by directly binding to Shh as a 
co-receptor can affect Shh signalling [176, 191]. More recently, the finding that 
only lipid-modified Hh could assemble into a polymeric complex [146] to 
enhance its solubility for long-range transportation might be linked to Hh by 
Shifted via interacting with both HSPGs and Hh proteins. Shifted is a secreted 
Wnt Inhibitory Factor (WIF) homologue. This study indicates that lipid 
modifications of Hh are not only essential for Hh/HSPGs interaction [145] but 
also critical for proper Ptc receptor anchoring through binding to Ptc. In 
contrast, lipid-unmodified Hh has great difficulty to be retained and poorly 
stabilised by the ECM and tends to diffuse freely [145]. Furthermore, studies 
implied that HSPGs might participate in promoting cell surface 
microdomains/lipid rafts in which the crucial molecules are assembled into 
functional complexes [177]. To sum up, HSPGs seem to facilitate the efficiency 
of these signalling cascades at various levels, including secreting, retaining 
and stabilising ligands, and also providing accurate trafficking and appropriate 
targeting to ligand-receiving cells [173, 192,193]. 
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A Cardin-Weintraub sequence located in the N-terminal end of Shh is thought 
to be responsible for the binding of the morphogen to HSPGs and appropriate 
localisation of Hh proteins [18,206]. Nevertheless, studies provided by Chan 
suggested that the Cardin-Weintraub motif did not seem to be solely 
responsible for Shh/HSPG binding [207]. In this work, I set out to use DNA 
mutagenesis to determine hShh residues involved in Heparin binding. Then, 
using RT-PCR and immunoblot analyses of Gli1 and Ptc (Hh signalling target 
genes; detecting mRNA and Gli1/Ptc protein respectively) to analyse hShh 
signalling efficacy of mutated hShh that cannot interact with HSPGs in PANC1 
cells. Since, I use human cancer cells as my model system, this study would 
provide evidence to shed light onto the importance of HSPGs in hShh 
signalling and cell transformation. Ultimately, blocking this interaction could be 
a therapeutic option. 
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3-2.  Results 
3-2-1. Purification of human Sonic Hedgehog (hShh) proteins 
bacterially expressed in the pET41a(+) system 
To establish a purification system for hShh in vitro, pET41a(+)-hShhN was 
constructed as shown in Fig. 3-1. All the constructs were sequence-verified. 
 
IPTG induces the transcription of the gene coding for β-galactosidase, a 
hydrolase enzyme that catalyses the hydrolysis of β-galactosides into 
monosaccharides. IPTG intake is independent on the action of lactose 
permease, since other transport pathways are also involved. One advantage of 
IPTG for in vivo studies is that as it cannot be metabolised by E. coli its 
concentration remains constant and the rate of expression of lac 
operon-controlled genes is not a variable in the experiment. For induction, a 
sterile 1 M solution of IPTG is typically added by 1:1000 dilution into a 
logarithmically growing bacterial culture.  
 
In this study in order to determine whether IPTG concentration has an effect on 
the level of hShh-GST expression different IPTG concentrations were tested in 
induction assays, 0.1 mM and 1 mM (Fig. 3-2A). Both IPTG levels caused 
similar induction of hShhN-GST clone and the proteins all express to high 
levels. Next, to investigate the time required for Glutathione-Sepharose to 
interact with hShhN-GST fusion protein as the first purification step, a study of 
the time course of binding was performed over 2hr, 4hr and 6hr (Fig. 3-2B). 
The unbound fractions were obtained by centrifugation and analysed by 
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SDS/PAGE (4hr and 6hr results not shown), indicating that binding for 2hr at 
room temperature has reached the maximum binding capacity of the 
hShhN-GST fusion protein. 
 
After the fusion proteins were isolated from a cell extract by 
Glutathione-Sepharose affinity chromatography, to remove hShh proteins from 
Glutathione-Sepharose beads efficiently, the time course of recombinant 
Enterokinase (rEK) digestion was carried out for 2hr, 4hr, 6hr and overnight. 
The analysis of cleavage products was examined by Coomassie Blue-stained 
SDS-PAGE gels (Fig. 3-2C, left panel; only show 4hr results). It indicated that 
rEK cleavage is most efficient after 4hr incubation at room temperature. Then, 
after hShh isolation from Glutathione-Sepharose, EKapture Agarose was used 
according to the manufacturer’s recommendations to remove rEK from the 
hShh/rEK mixture. Purity of hShh proteins was assayed by Coomassie 
Blue-stained SDS-PAGE gels (Fig. 3-2C, right panel) and concentration of 
purified proteins was estimated by measuring absorbance at 280 nm using a 
Nanodrop spectrophotometer. Gel electrophoresis here provided showed good 
quality of purified proteins.  
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Figure 3-1. Cloning map of hShhN-GST fragments. A: pET-41a(+) vector 
designed for cloning and high-level expression of peptide sequences fused 
with the 220 aa GST•Tag™ protein. The red line indicates the insertion sites of 
hShh fragments. Unique sites are shown on the map. Note that the sequence 
is numbered by the pBR322 convention, so the T7 expression region is 
reversed on the circle map. B: PshAI-hShhN-SacI PCR fragment used for 
expression/purification in bacteria. C: PshAI blunt cloning site. Vector-encoded 
sequence can be completely removed when cloning into the PshAI site and 
then cleaving the GST fusion protein with rEK. D: pET-41a(+) 
cloning/expression regions. 
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Figure 3-2. Purification of hShh proteins expressed in bacteria. A: 0.1 mM 
and 1 mM IPTG induction of hShhNC24II in the GST system.  B: induction 
and purification of hShhNC24II using the GST system. BI: cell lysate before 
induction; AI: cell lysate after induction with 0.1 mM IPTG; TCL: total cell lysate 
with 0.2% lysozyme; GSB: Glutathione-Sepharose bound fraction; Un: 
Glutathione-Sepharose unbound fraction. Blue arrow shows predicted size of 
hShhN-GST fusion protein with 19 kDa hShhN and 30 kDa GST.  C: analysis 
of rEK digestion of hShhN-GST fusion proteins. The left panel shows the 
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pattern of hShh proteins digested by rEK for 4hr. The right panel provides the 
purity of hShh proteins after removal of rEK from the hShh/rEK mixture. Red 
arrow shows predicted size of hShhN protein at 19 kDa. Green arrow shows 
predicted size of GST at 30 kDa. Blue arrow shows predicted size of 
undigested hShhN-GST fusion protein at 49 kDa. 
 
 
3-2-2. Characterisation of purified hShh proteins via Western 
blots 
The correct three-dimensional structure is essential to function.  To examine 
the bioactive folding of mutated hShhN proteins purified from E. coli, two 
different hShh antibodies, 5E1 (Shh neutralising antibody) and H160, were 
used in Western blotting (Fig. 3-3A) and dot blotting (Fig. 3-3B). The former 
was used to define the native folding of purified hShh proteins [169,194,221]; 
the latter was used to prove equal amount of purified hShh proteins were 
loaded. However, to determine if protein folds into its characteristic and 
functional three-dimensional structure from random coil, further techniques for 
studying protein folding will need to be used; e.g. circular dichroism (CD), dual 
polarisation interferometry, X-ray crystallography and NMR.  Folded 
structures of proteins are routinely determined by X-ray crystallography and 
NMR. Dynamic methods to characterise protein folding such as dual 
polarisation interferometry and CD provide a measurement of conformation 
and conformational change rather than structure. 
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Figure 3-3. Characterisation of purified hShh proteins by immunoblotting. 
Purified hShh proteins were analysed by Western blot (A) and dot blot (B) with 
two Shh antibodies, H160 and 5E1. 
 
 
 
3-2-3. K37/38 and K178 of hShh play crucial roles in Heparin 
interaction 
Previous studies in Drosophila [115] and vertebrate systems [136] suggested 
that by forming a multimeric complex with specific HSPGs - Perlecan and 
Glypican – the efficiency of Hh signalling could be facilitated. However, this 
mechanism is still unclear in the human system. Putative hShh residues 
involved in heparin binding were based on modelling of Shh-heparin 
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interaction provided by Dr. Barbara Mulloy (NIBSC, personal communication; 
Fig. 3-4). This modelling supported the role of the known Shh 
Cardin-Weintraub motif in heparin interaction but suggested the involvement of 
another lysine residue, K178. To examine whether hShh could interact with 
HSPGs, I established a simple bench-top heparin affinity assay (Fig. 3-5) and 
verified the result in the presence of competing free heparin (data not shown). 
The hShh bound to heparin, albeit quite weakly, and was competed by heparin. 
This suggests that hShh has potential to form a complex with HSPGs, as 
already known.  
 
Next, to verify previous results another system was used to determine key 
residues on hShh involved in HSPG binding, involving column chromatography 
on a heparin-Sepharose column with gradient elution (Fig. 3-6). Again, elution 
profiles from column chromatography together with results from gel 
electrophoresis provided in Fig. 3-2C (right panel) both demonstrate good 
quality of purified proteins. In this assay, mutated hShh proteins (ShhNC24II, 
ShhNC24II/K37.38S, ShhNC24II/K178S, ShhNC24II/K37.38.178S and 
ShhNC24II/K74S) were expressed and purified from bacteria and were applied 
to Heparin affinity chromatography and eluted by a 0 to 0.7 M NaCl gradient 
(Fig. 3-6). Fig. 3-6B and 3-6C show that ShhNC24II eluted in 0.54 M NaCl 
(consistent with previous binding assay data), similarly to ShhNC24II/K74S 
(0.53 M NaCl), whereas ShhNC24II/K37.38S (Fig. 3-6D) and 
ShhNC24II/K178S (Fig. 3-6E) show reduced interaction, being eluted in 0.4 M 
NaCl and 0.3 M NaCl fractions respectively. Very interesting to note, when I 
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examined the triple mutant, ShhNC24II/K37.38.178S, the elution pattern 
showed much lower binding efficacy, eluting at 0 - 0.06 M NaCl (n=5), 
suggesting that K37, K38 and K178 on hShh play critical roles in HSPG 
binding. 
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Figure 3-4. Computer modelling of heparin/Hh and heparin/hShh. The 
computer modelling suggests interaction between heparin to Drosophila Hh (A) 
and heparin to hShh (B). Heparin is shown as blue and purple in A and B 
respectively. Hh and hShh are shown as green in A and B respectively 
(Barbara Mulloy, personal communication). 
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Figure 3-5. Bench-top heparin/hShh proteins binding assay. 5 µg of 
purified hShhN proteins were applied at room temperature to a 
Heparin-Sepharose column equilibrated with 10 column volumes (CVs) of PBS. 
Then, the column was washed with 10 CVs of this buffer and eluted stepwise 
with 0.24, 0.33, 0.5, 1, 1.5 and 2 M NaCl in PBS. Totally, over 20 CVs were run 
at a gravity rate and each fraction was collected as 1 CV. F: 1st CV flow through; 
W1: Wash 1 fraction with 10 CVs 0.15 M NaCl; W2: Wash 2 fraction with 5 CVs 
2 M NaCl; 0.24: eluate with 1 CV 0.24 M NaCl; 0.33: eluate with 1 CV 0.33 M 
NaCl; 0.5: eluate with 1 CV 0.5 M NaCl; 1: eluate with 1 CV 1 M NaCl; 1.5: 
eluate with 1 CV 1.5 M NaCl. After collection, 10 µl volumes of each fraction 
were spotted on nitrocellulose membrane and probed with anti-Shh 5E1. 
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Figure 3-6. Characterisation of purified hShh proteins with heparin 
affinity chromatography via ÄKTA Purifier system. The individual Heparin 
binding efficacy was determined via Heparin-Sepharose chromatography (A-F) 
with a liner gradient of 0-0.7M NaCl. Relative affinities of hShh variants for 
heparin, represented by [NaCl] required for elution, are shown in G. In A-F, the 
X-axis represents time. Blue line shows OD 280 absorbance. Green line 
demonstrates elution gradient of 0-0.7M NaCl phosphate buffer. Red line 
represents the conductivity curve. Column: HiTrap Heparin HP, 0.7 x 2.5 cm; 
Flow Rate: 0.5 ml/min at room temperature; Buffer A: 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4; Buffer B: 0.7 M NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4.  
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3-2-4. Bioactivity of mutated hShhs in C3H10T1/2 cells 
To examine biological function of different hShh proteins, I took advantage of 
C3H10T1/2 osteoblast precursor cells which induce alkaline phosphatase (AP) 
when stimulated by Shh [188]. As shown in Fig. 3-7A, both ShhNC24II and 
ShhNC24II/K74S supplemented medium (1µg/ml) induced C3H10T1/2 
differentiation into AP-producing osteoblasts, evidenced by increased AP 
activity detected by 405nm absorbance due to p-nitrophenylphosphate 
substrate hydrolysis, demonstrating competent biological activity of these 
purified hShh proteins. In contrast, medium containing ShhNC24II/K37.38S 
and ShhNC24II/K178S were greatly reduced in their activity in the C3H10T1/2 
assay with 0.60
±
0.14 and 0.32
±
0.09 A405 respectively. Furthermore, 
ShhNC24II/K37.38.178S triple mutant exhibited a more significant loss of AP 
activity with only 0.17
±
0.13 A405. However, when I increased hShh proteins to 
2 µg/ml the differences of AP activity between hShhs-containing medium 
become less significant - A405 ShhNC24II: 1.18
±
0.11; ShhNC24II/K74S: 1.19
±
0.08; ShhNC24II/K37.38S: 0.60
±
0.14; ShhNC24II/K178S; 0.32
±
0.09 and 
ShhNC24II/K37.38.178S; 017
±
0.13 (Fig. 3-7A).  
 
Next, to verify whether that the induced AP activity was due to hShh proteins, I 
used Shh-neutralising antibody 5E1 [194] as a specific Shh inhibitor during 
C3H10T1/2 differentiation (Fig. 3-7B). As expected, the biological activity of 
Shhs was significantly inhibited by 5E1 co-treatment - A405 ShhNC24II: 0.41
±
0.07; ShhNC24II/K74S: 0.41
±
0.05; ShhNC24II/K37.38S: 0.20
±
0.05; 
ShhNC24II/K178S: 0.15
±
0.01 and ShhNC24II/K37.38.178S: 0.08
±
0.01 (Fig. 
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3-7B). The above data showed that ShhNC24II/K37.38S, ShhNC24II/K178S 
and particularly ShhNC24II/K37.38.178S mutants were greatly reduced in 
activity both in their ability to bind Heparin and to induce AP expression, 
suggesting that both K37.38 and K178 are significant in Shh biological activity. 
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Figure 3-7. Differentiation of C3H10T1/2 Osteoblast Precursor Cells - AP 
assay. C3H10T1/2 osteoblast precursor cells were cultured in the presence of 
different hShh mutants from 300-2000 ng/ml for 5 days (A). The relative 
amount of Shh-induced AP activity was measured as described in Materials 
and Methods to determine biological activity of the morphogen. As a control, 
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Shh-treated cells were incubated with 5E1 anti-Shh to demonstrate specificity 
of Shh-induced AP (B). Values are mean±S.D., n=9 in each group, *p-value 
<0.001 compared to control group ShhNC24II, **p-value <0.001 compared to 
5E1 treatment group, ‡p-value <0.01 compared to 5E1 treatment group. 
 
 
3-2-5. ShhNC24II/K37.38.178S is deficient in causing 
increased signalling through the Shh pathway in PANC1 cells 
To provide further direct evidence that mutated hShhs were deficient in Shh 
signalling activity, semi-quantitative reverse transcription-polymerase chain 
reaction (RT-PCR) and Western blots were carried out on PANC1 cells 
pre-treated with 1 µg/ml hShhs for 24hr and 48hr respectively. Therefore, the 
signalling activity obtained from both assays will be the consequence of 
endogenous hShh plus exogenous purified Shh proteins in PANC1 cells.   
 
The quality of extracted total RNAs is provided in Fig. 3-8A, showing three 
clear distinguishable rRNA species, 28S, 18S and 5.8S. Isolated RNAs were 
quantified using UV absorption using a NanoDrop spectrophotometer 
measured at 260 and 280 nm. RNA has its absorption maximum at 260 nm 
and OD A260/A280 ratio is used to assess the RNA purity of an RNA preparation. 
Pure RNA has an A260/A280 of 2.1. In this study, values of A260/A280 between 
1.8-2.0 were detected in all five conditions (Fig. 3-8A) indicating good quality of 
isolated RNAs. In RT-PCR (Fig. 3-8B, D), GAPDH and β -Actin were used as 
loading controls. Ptc and Gli1 were used as indicators of Shh pathway activity, 
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as they are targets of this pathway. In comparison with untreated cells, 5E1 
treatment strongly reduced both Ptc and Gli1 expression by 70% and 79% 
respectively. On the other hand, compared to ShhNC24II and 
ShhNC24II/K74S, both ShhNC24II/K37.38S and ShhNC24II/K178S showed 
decreased Ptc and Gli1 mRNA level by > 20% and > 25% respectively (P< 
0.001), whereas Shh and Smoothened (Smo) showed no significant difference. 
More importantly, ShhNC24II/K37.38.178S showed a further reduction in Ptc 
and Gli1 by > 28% and > 47% respectively (P< 0.001). 
 
Next, immunoblotting was carried out to verify RT-PCR results (Fig. 3-8E, F). 
Interestingly to note that in Western blots of Ptc both ShhNC24II/K178S and 
ShhNC24II/K37.38.178S showed strong reduction in protein level by 44% and 
60% respectively (P< 0.0003), comparing to ShhNC24II and ShhNC24II/K74S 
treated condition. On the other hand, less Gli1 be stimulated by 
ShhNC24II/K178S and ShhNC24II/K37.38.178S with 53% and 57% reduction 
respectively (P< 0.005) compared to ShhNC24II and ShhNC24II/K74S group. 
To sum up, modifications of wild type Shh through potential HSPG binding 
sites (K37.38 and 178) resulted in a large reduction in the activity in both 
C3H10T1/2 and PANC1 assays (Fig. 3-7 and 3-8), suggesting that HSPG 
binding is crucial to Shh signalling in human model system.  
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Figure 3-8. Biological functional assay of hShh proteins in PANC1 cells 
by Semi-quantitative RT-PCR and immunoblotting. To study the role of 
mutated hShhs in Shh signalling in a human model system, expression levels 
of Ptc and Gli1 were examined by both RT-PCR and Western blot in PANC1 
cells after hShh proteins treatment. The PCR product agarose gel and 
immunoblotting data are provided in B and D respectively. Quantified results 
are given in C and E. Values are mean±S.D., n=9 in each group in RT-PCR 
experiments, * p-value <0.0001 compared to untreated group. ‡ p-value 
<0.001 compared to ShhNC24II group. In the Western blotting assay (n=4), * 
p-value <0.0001 compared to untreated group. ‡ p-value <0.001 compared to 
ShhNC24II group. The total extracted RNAs are shown in A. 
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3-2-6. ShhNC24II or ShhNC24II/K74S but not 
ShhNC24II/K37.38.178S can rescue inhibition of PANC1 
proliferation caused by hShh RNAi knockdown 
To determine the effects on PANC1 proliferation of mutated hShhs that cannot 
interact with HSPGs properly, hShh RNAi KD and purified-Shh co-treatment 
were used, combined with cell proliferation analysis by CFSE incorporation 
followed by flow cytometry analysis. In this assay, cells are loaded at the start 
of the experiment with the dye CFSE which passively diffuses into cells; it is 
non-fluorescent until the acetate groups are cleaved by intracellular esterases 
to yield highly fluorescent carboxyfluorescein (CF). During cell division, CF is 
distributed equally between the two daughter cells, which therefore have half 
the fluorescence of the parents. Dilution of CF by cell division over the 
time-course of the experiment is therefore a measure of proliferation. The 
histogram of flow cytometry is shown in Fig. 3-9 A-J. The quantitative data are 
provided in Fig. 3-9 K. I set out to investigate whether PANC1 proliferation is 
Shh-dependent by treating cells with 5E1, the inhibitory antibody of Shh, and 
the result was verified with Shh KD. According to my data from 30,000 cells in 
each condition, CF intensity in the 5E1 D1-treated group (5E1 treated on Day 1, 
Fig. 3-9 B) is ~30 times higher than untreated cells (Fig. 3-9 A), suggesting that 
untreated PANC1 cells reproduce 4-5 times more than 5E1-treated cells in 8 
days. Moreover, the 5E1 D4 group (5E1 treated on Day 4, Fig. 3-9 C) used to 
mimic the kinetics of RNAi KD in vivo, shows a similar number as Shh KD with 
~8 times higher CF intensity compared to untreated cells. Both results confirm 
that PANC1 proliferation is Shh-dependent. A scrambled siRNA (Fig. 3-9 E) 
  
113
used as a negative control for Shh KD showed a similar profile to untreated 
cells. 
 
Interestingly, 7 days after treatment the profile of flow cytometry in Shh KD 
cells treated with either active ShhNC24II or ShhNC24II/K74S revealed a 
similar pattern as untreated cells (MFI < 1000; Fig. 3-9 F, G), suggesting that 
both ShhNC24II and ShhNC24II/K74S proteins are capable to rescue reduced 
PANC1 proliferation caused by Shh KD (P< 0.00001).  
 
On the contrary, purified ShhNC24II/K37.38S (Fig. 3-9 H) and 
ShhNC24II/K178S (Fig. 3-9 I) proteins added to culture medium showed less 
ability to rescue PANC1 proliferation caused by Shh KD with ~6 times increase 
in MFI (~4500) compare to untreated cells (P< 0.00001). Furthermore, 
ShhNC24II/K37.38.178S treatment of Shh KD cells showed a similar pattern 
with Shh KD alone (~8 times increase in MFI, ~6500) compared to untreated 
cells (P< 0.00001), indicating that ShhNC24II/K37.38.178S is defective in 
stimulating PANC1 proliferation compared to ShhNC24II and ShhNC24II/K74S. 
The above results indicate that HSPGs binding plays an important role in 
PANC1 proliferation through Shh signalling due to the fact that ShhNC24II or 
ShhNC24II/K74S can rescue inhibited PANC1 caused by hShh RNAi KD but 
the triple mutant ShhNC24II/K37.38.178S is unable to do so effectively. 
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Figure 3-9. The role of mutated hShh proteins in PANC1 cell proliferation. 
A-J show profiles from flow cytometry. The quantified data are given in K. Both 
5E1 treatment on Day 1 (5E1 D1) and Shh KD were used to examine if PANC1 
proliferation is Shh dependent. 5E1 treatment on Day 4 (5E1 D4) was used to 
mimic RNAi KD kinetics in vivo. The level of maximum labeling was 
determined by treating cells with CFSE just before flow cytometer assessment. 
To study the effect of different Shh proteins in PANC1 proliferation, 8 days 
after Shh siRNA transfection /hShh treatment the cells were analysed by flow 
cytometry. The X-axis of A-J and Y-axis of K show the level of CF intensity 
observed from 30,000 cells. The trend of cell proliferation is indicated by the 
green arrowhead. The experiments were repeated three times in triplicate, and 
statistical significance was measured by using the two-tailed t test (**, P< 
0.0001 compared to untreated group; ‡, P< 0.0001 compared to Shh KD 
group. 
 
 
 
3-2-7. ShhNC24II/K37.38.178S cannot rescue inhibited PANC1 
invasion caused by hShh KD  
To investigate the contribution of Shh mutations to invasive potential of PANC1 
cells, I carried out invasion assays by exogenous Shhs treatment combined 
with endogenous Shh RNAi KD. To examine whether PANC1 invasion is 
dependent on Shh signalling I started by determining the effect on PANC1 
invasion of 5E1 treatment. The results (Fig. 3-10) show a significant decrease 
in the number of invading cells after 5E1 treatment (33
±
8 cells/well) compared 
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with untreated control cells (271
±
25 cells/well). These data were then verified 
by Shh KD giving 43
±
11 cells/well. These results suggest that the invasive 
ability of PANC1 cells is at least partly due to Shh signalling. Interestingly, 
when I combined Shh KD and either ShhNC24II or ShhNC24II/K74S in the 
invasion assay, a significant increase in the number of invasive PANC1 cells 
was observed (325
±
32 and 302
±
45 cells/well respectively) compared with 
Shh KD cells, suggesting that ShhNC24II or ShhNC24II/K74S are able to 
restore inhibited PANC1 invasion caused by Shh KD. In contrast, 
ShhNC24II/K37.38S and ShhNC24II/K178S combined with Shh KD showed 
significant decrease in the number of invasive PANC1 cells with 192
±
15 and 
191
±
18 cells/well respectively. Furthermore, ShhNC24II/K37.38.178S 
combined with Shh KD reduced invasion to a level (86
±
17 cells/well) similar to 
that observed for Shh KD cells, indicating that ShhNC24II/K37.38S, 
ShhNC24II/K178S and particularly ShhNC24II/K37.38.178S provide less 
stimulus for PANC1 invasion. To sum up, the results of the above studies 
indicate that HSPGs binding plays a crucial role in PANC1 invasion due to Shh 
signalling. 
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Figure 3-10. Biological function of mutated hShh proteins in PANC1 cells 
invasion. I set out to determine whether PANC1 invasion is Shh dependent 
using 5E1 treatment and Shh RNAi KD. To study the effect of different Shh 
proteins in PANC1 invasion, 72hr after RNAi transfection/Shhs treatment the 
cells were plated onto Matrigel invasion chambers for 24hr. Cells that had 
migrated from the upper to the lower side of the filter were photographed (A) 
and counted with a light microscope (10 fields/filter, B). The experiments were 
repeated four times, and statistical significance was measured by using the 
two-tailed t test (*, P< 0.001 compared to untreated group; ‡, P< 0.0001 
compared to ShhNC24II/Shh KD group). 
 
 
 
3-2-8. ShhC24II/K37.38.178S is defective in forming 
multimeric complexes in PANC1 cells  
To evaluate the ability of mutated hShhs in formation of Shh multimeric 
complexes in extracellular matrix (ECM), gel filtration followed with Shh dot 
blot were carried out for PANC1 cells. The efficacy of the Shh KD was 
examined by Western blotting of culture medium (Fig. 3-11A). A 19kDa band 
was observed and more secreted Shh was found in medium from both 
untreated cells and scrambled RNAi-treated cells than from Shh KD cells, 
providing good evidence that Shh KD did reduce Shh expression. To prevent 
possible malfunction of purified Shh proteins on oligomerisation when applied 
exogenously to PANC1 cells, a mammalian overexpression vector- 
pcDNA-DEST40-hShh was used in the assay. By Shh dot blotting of gel 
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filtration fractions (Fig. 3-11B), the majority of secreted Shh in PANC1 control 
untreated culture medium forms large multimeric complexes and only a small 
portion of Shh migrates as monomers (2.6
±
1.2%, P< 0.0001), confirming the 
results of a previous study [188]. On the contrary, in Shh RNAi-treated cultured 
medium the total amount of Shh was much reduced (>90% reduction 
compared with untreated control cells) and higher quantities of Shh monomers 
were detected (12.7
±
4.5%, P< 0.0001), nearly 6 times higher than untreated 
control medium, whereas scrambled RNAi-treated medium shows a similar 
pattern to control medium with a ratio of 1.9
±
1.3% monomer (P< 0.0001). As 
expected, ShhNC24II or ShhNC24II/K74S expression combined with Shh KD 
treatment, either had no difference from control or in most instances resulted in 
a slight decrease in Shh monomerisation with 1.2
±
0.9% and 1.1
±
0.8% 
respectively (P< 0.0001), providing evidence that transfected 
pcDNA-DEST40-hShh and pcDNA-DEST40-hShhK74S are capable to form 
multimeric complexes in PANC1 cells. Interestingly, when I analysed medium 
from pcDNA-DEST40-hShhK37.38S-expressing and 
pcDNA-DEST40-hShhK178S-expressing Shh KD cells, a strong increase in 
monomerisation was observed; 25.5
±
5.7% and 20.4
±
4.6% respectively (P< 
0.001). Notably, a dramatic increase in monomer formation was detected in 
pcDNA-DEST40-hShhK37.38.178S-expressing Shh KD cells (85.5
±
9.7%, P< 
0.001).  In combination, I conclude that wild type hShh and hShhK74S are 
able to form multimeric complexes when expressed in PANC1 cells, but 
hShhK37.38.178S is not, and the hShhK37.38S and hShhK178S mutants 
show an intermediate phenotype. 
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Figure 3-11. The role of mutated hShh proteins in Shh multimeric 
complex formation. 72hr after RNAi transfection, the culture media were TCA 
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precipitated and examined by Western blot for Shh (A). In B, to examine the 
role of mutated hShh proteins in Shh oligomerisation, 16hr after Shh siRNA 
treatment hShh overexpression vectors were transfected into the cells followed 
by 48hr incubation. Then, the media were subjected to gel filtration 
chromatography (Superdex200 10/300 GL column). After TCA precipitation, 
the fractions were probed by Shh dot blot (B). Monomerisation factor (%) = 
(Monomer / Monomer + Multimer) X 100%. 
 
 
 
3-3.  Discussion 
HSPGs are tremendously diverse, due to the involvement of the genes 
encoding core proteins, the sulfotransferases, sugar transporters, 
glycosyltransferases, sulfatases and acetylating enzymes. As HSPGs interact 
with many growth factors and other molecules, analyses of mutants that 
interfere with individual steps of proteoglycan synthesis are difficult to interpret. 
To identify the functions of HSPGs for Shh signalling, I took an alternative 
approach by generating mutant Shh proteins that cannot bind heparin properly. 
In this work, I developed an in vitro system to express and purify hShh proteins. 
In both a bench-top elution method and heparin affinity column 
chromatography, I found that mutations in putative HSPG-binding sites of Shh, 
the Cardin-Weintraub motif (K37.38) and a novel residue K178, interfere with 
heparin binding significantly. The in vitro binding assay showed that heparin 
binding to wild-type Shh is disrupted by 0.54 M NaCl, but by only 0 - 0.06 M 
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NaCl for the K37.38.178S triple mutant. This is the first evidence indicating that 
not only the Cardin-Weintraub motif, but also K178 of Shh can be a significant 
residue involved in HSPGs binding. 
 
C3H10T1/2 differentiation, carried out as assessed by alkaline phosphatase 
(AP) induction, is a standard assay for Shh activity. I found 2-4 times lower AP 
induction by mutants K37.38S (0.60
±
0.14) and K178S (0.32
±
0.09) 
compared to wild-type Shh (1.18
±
0.11) and the control mutation K74S (1.19
±
0.08), though high doses of Shh proteins were required, consistent with the 
lack of post-translational lipid modifications of the bacterially expressed 
proteins. These results indicate that AP induction by the Shh signalling 
pathway is associated with HSPGs and ligand interaction. Previous studies 
reported that Shh responses are mediated primarily by the transcription factors 
Gli1, Gli2, Gli3 [22-24,195] and the receptor Ptc. Unlike Gli2 and Gli3, which 
can function as either transcriptional activators or repressors, Gli1 only 
functions as an activator, and only one isoform of Gli1 has been identified. 
Here, I analysed the expression of Gli1 and Ptc in Shh-pretreated PANC1 cells. 
Consistent with the data above, both induced mRNA and protein levels of Gli1 
and Ptc are lower following treatment by the mutant K37.38.178S than were 
acutely stimulated with wild-type Shh and K74S mutant. Ptc and Gli1 protein 
level are respectively 60% and 57% lower after treatment with the 
K37.38.178S triple mutant than for wild-type Shh. Together, these findings 
indicate that Shh-HSPGs interactions mediated by the Cardin-Weintraub motif 
and the novel residue 178K are significantly required for Shh signalling activity. 
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However, using a mammalian expression vector in both C3H10T1/2 
differentiation assay and PANC1 system would provide a better option to study 
the biological function of mutated Shh proteins; since this approach can 
preclude the possibility of misfolding of bacterially purified proteins.  
 
A number of Shh responsive genes have been identified, including genes that 
are involved in proliferation and tissue patterning [196-202] e.g. Gli2, N-myc, 
Gli3, Cyclin D1, Cyclin D2 and Bmi-1. In addition, it has also been shown that 
Cyclin D1, Cyclin D2 and Bmi-1 gene targets that require Shh-HSPG 
interactions are significant in tumour stem cell biology [196,197].  Also, it is 
interesting to note that Shh-dependent cancer growth can be stimulated via 
glypican overexpression in several cases, e.g. prostate cancer, pancreatic 
carcinoma and rhabdomyosarcoma [203,204]. In this work, I asked whether 
interactions with HSPGs can modulate the pattern of Shh-responsive gene 
induction and the biological responses to Shh. 
 
It has been reported that 5E1 is a specific inhibitor of the Shh pathway by 
binding to Shh as a neutralising antibody and inactivating Shh signalling [205]. 
I employed 5E1 to block the Shh signalling pathway in PANC1 cells and to 
determine the effect of the pathway on proliferation and invasiveness of 
PANC1 cells. A significant decrease in tumour cell proliferation (4-5 times 
lower within 8-days) and an eightfold reduction in invasiveness were observed, 
suggesting that Shh signalling has a critical and central role in pancreatic 
tumour cell growth and contributes to malignant transformation. 
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By flow cytometry, I directly demonstrated that changing wild-type Shh to either 
K37.38S or K178S mutant results in a reduced proliferation pattern; an even 
more marked effect was noted with the K37.38.178S triple mutant, which 
revealed a threefold reduction in tumour proliferation within 8 days. These 
findings indicate a close relationship between the Shh-HSPGs binding and the 
proliferation ability of pancreatic cancer cells.  
 
In the invasion assay, I observed a decrease in invasive cells by K37.38S (192
±
15 cells/well) or K178S (191
±
18 cells/well) treatment compared to wild-type 
Shh (325
±
32 cells/well) and control K74S mutant (302
±
45 cells/well). Not 
surprisingly, the triple mutant K37.38.178S resulted in a fourfold reduction in 
invasive cells compare with wild-type Shh and control mutant. These data 
indicate that Shh interacts with HSPGs in PANC1 cells to influence the 
invasive ability of the pancreatic cancer cells. 
 
Together, these findings suggest that Shh-HSPGs interactions promote 
PANC1 cells oncogenic properties at multiple levels, including both 
proliferation and invasion, highlighting the widespread significance of 
proteoglycans in tumorigenesis and also pointing out an important mediator of 
the malignant biological behaviour of pancreatic adenocarcinomas in humans. 
However, to prevent from possible malfunction of bacterially purified proteins 
(e.g. misfolding of purified proteins) using a mammalian expression vector 
would be a better way to examine the functional role of mutated Shh proteins in 
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PANC1 tumourgenesis and malignant transformation.  
   
There are two potential mechanisms to explain the effects of proteoglycans on 
Shh-induced proliferation and invasion in PANC1 cells. One is that HSPGs 
provide Shh accurate trafficking and targeting on receiving cells.  Previous 
studies using mutations in the glypican Dally-like, mutations in the Ext gene 
family (the HSPG-synthesising enzymes) and truncation of the 
Cardin-Weintraub motif have suggested that HSPGs are critical for appropriate 
localisation of Hh proteins [55,138,139,206]. A second potential mechanism is 
that binding of Shh to HSPGs modulates stability of Shh in ECM via forming a 
multimeric complex. In this work, to address this possibility I asked whether 
mutated Shh proteins had altered ability to form multimers. 
 
In the oligomerisation study, by expressing the Cardin-Weintraub K37.38S 
mutant instead of wild-type Shh or control mutant K74S I observed an increase 
in Shh monomer ratio in the medium. Interestingly, the K178S mutant resulted 
in a similar pattern as the Cardin-Weintraub mutant. From the above data, here 
I hypothesise for the first time that K178 of Shh may play key a role in Shh 
multimeric complex formation via binding with HSPGs. Consistent with this, in 
the 3D structure of Shh, K178 is located close to the HSPG-binding groove 
containing the Cardin-Weintraub motif (K. Grobe, personal communication). 
The further increased monomer ratio (over 80%) found for the K37.38.178S 
mutant is in agreement with the suppressed initiation and maintenance of 
PANC1 cells revealed by the above proliferation and invasion data.  
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Thus, the above data provide supportive evidence leading to the idea that one 
mechanism by which Shh-HSPGs interactions stimulate Shh signalling is by 
forming stablised multimeric complexes in ECM [188]. On the other hand, a 
previous study in transgenic mice has shown that mutations in the 
Cardin-Weintraub motif of Hh proteins interfere with proteoglycan binding, but 
do not alter Ptc affinity [207]. However, in this case we cannot exclude the 
possibility that reduced PANC1 proliferation and invasion induced by the K178 
mutant is also due to the loss of Ptc interaction. In summary, the findings 
presented in this work provide a new perspective that Shh-HSPGs interactions 
promote proliferation and invasion in PANC1 cells, via forming a multimeric 
complex in ECM to facilitate stability and solubility of Shh proteins. 
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129
4. The Role of Hhat in Human Shh Signalling 
 
4-1.  Introduction 
Post-translational lipid modifications are known in other secreted signalling 
molecules, i.e. the Wnt protein family that is another conserved family in 
vertebrates and invertebrates, as well as in the Epidermal Growth Factor 
Receptor (EGFR) ligand Spitz [208]. However, Hh proteins are unique in terms 
of being dually lipid-modified with a fatty acid and cholesterol to be fully active 
[159]. 
 
Palmitoylation is the attachment of fatty acids from Palmitoyl-Coenzyme A 
(Pal-CoA) as a lipid donor, usually to cysteine residues of proteins. Unlike 
myristoylation and farnesylation, palmitoylation provides modified cytoplasmic 
proteins accurate trafficking from internal membranes to the plasma 
membrane [6] and controls their targeting to membranes or membrane 
subdomains, affects protein–protein interactions, or influences the stability of 
proteins. In addition, studies demonstrate that palmitoylation can facilitate the 
efficiency and specificity of signalling through not only correctly guiding a 
signalling molecule to its target within the cell but also membrane-anchoring at 
specific cell surface microdomains/lipid rafts [59,146]. Moreover, it has been 
shown that dual lipidation is critical not only for the interactions between Hh 
and Ptc but also for forming a suitable Hedgehog (Hh)- hepaaran sulfate 
proteoglycans (HSPGs) complex to target at the Hh-receiving cell [146]. It is 
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now appreciated that Ptc might be located in lipid rafts/microdomains which 
provide platforms for signal transduction and intracellular sorting [160]. Hence, 
the interactions between particular HSPGs, Hh and Ptc are significant to Hh 
spreading through the epithelium surface, as well as precise Hh reception.  
 
It is evident that the N-terminal palmitoylation of Hh is facilitated by the product 
(Hhat) of the hedgehog acyltransferase gene (also known as skinny hedgehog, 
sightless, central missing and raspberry) [141]. However, the mechanism of 
this N-acylation is still unclear [209]. Structurally, Hhat shares homology with 
the membrane-bound O-acyltransferases (MBOAT) family (Fig. 4-1), the 
members of which are enzymes that generally catalyse the addition of a fatty 
acid to a hydroxyl group [29]. Hhat also shares homology with Porcupine (Porc) 
in Drosophila and its C. elegans homologue Mom-1 [29], two putative 
acyltransferases that are also part of the MBOAT protein family and are 
responsible for the palmitoylation of Wg, a morphogen involved in embryonic 
patterning in Drosophila, and its human homologues Wnts [29,59]. Another 
MBOAT family member, GOAT, has been implicated in metabolic activation of 
the peptide hormone ghrelin by specifically octanoylating ghrelin on its critical 
serine-3 residue [61]. 
 
From various studies we hypothesise that the mechanism by which Hhat adds 
a palmitate to the N-terminal of the cysteine-24 residue in Shh [34] may be 
solely enzymatic, chaperone-like or a combination of both. For instance, Hhat 
contains the characteristic histidine residue conserved in almost all members 
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of the MBOAT family [29]. It is believed that this conserved histidine residue- 
H379 may represent the active site of the putative acyltransferase [210]. 
Based on a very recent study, the Hhat H379A mutant retains 50% activity 
compared with wild-type Hhat, suggesting that this conserved Histidine is not 
the only factor required for catalysis. Combined with the fact from kinetic 
analyses that purified H379A Hhat showed similar affinity to Pal-CoA as 
wild-type Hhat, suggesting H379 may involved in Shh recognition and 
interaction. Moreover, point mutation of the adjacent residue- W378A caused a 
more reduced Hhat activity. Also, the fact that Hhat being a member of 
palmitoyl acyltransferases (PATs) with a known enzymatic function in 
palmitoylating a group of proteins [14] leads the argument towards the 
mechanism being enzymatic. On the other hand, Pal-CoA, the co-substrate of 
acyltransferases, instead of being free in the cell is bound to the acyl-CoA 
binding protein (ACBP) and therefore may require a transporter that facilitates 
its entry into the lumen of the secretory pathway where palmitoylation of Shh 
presumably occurs [162]. Also, the fact that Hhat is a multi-spanning 
transmembrane protein raises the speculation that it may play a role as a 
transporter of Pal-CoA. 
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Figure 4-1. MBOAT family members topology. MBOAT (membrane-bound 
O-acyltransferase) family members that promote protein acylation - Hhat, Porc 
and GOAT - contain multiple membrane-spanning domains. These 
palmitoylacyltransferases (PATs) are responsible for attaching fatty acids 
(originating in the cytoplasm in the form of activated CoA esters) to secreted 
signalling proteins (SSP), such as Hhs, Wg/Wnts and ghrelin, within the lumen 
of the secretory pathway. The histidine shown is conserved in almost all 
members of the MBOAT family and may contribute to the active site of the 
putative acyltransferase (from ref.147). 
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4-2.  Results 
4-2-1.  Human Hhat antibody generation 
To determine the localisation of endogenous human (h) Hhat and to study the 
biological role of hHhat in vivo, we set out to generate an hHhat antibody 
based on an anti-peptide approach. In addition, to enrich the diversity of 
antibodies that are produced and to short-circuit potential failure if a single 
antigen does not produce an immune response, a multiple-peptide 
coimmunisation approach was used. Other benefits from the multiple-peptide 
immunisation strategy include: 1) Higher chance of finding best antibodies 
from the pool of antibodies generated. After isolation, the individual peptide 
antibodies can be characterised for application such as immunoprecipitation. 2) 
Lower cost than separate protocols. 3) Increase the chance for the ability to 
generate more than one peptide antibodies to one protein due to exposure of 
greater number of selected target epitopes which can be isolated using 
specific peptide affinity purification. 
 
In this study, two predicted extramembrane domains from hHhat were chosen 
as suitable epitopes (shown in Fig. 4-2, underlined with blue line). The 
sequences of the peptides are: KQMQQQEHDSLKASL (a.a.227 – a.a.241) 
and CYSHVGIAWAGTYATD (a.a.478 – a.a.493). These were coupled to KLH 
carrier and co-immunised into rabbits (Materials and Methods). After 
characterising potential antibodies by examining subcellular fractionation of the 
antigens (Section 4-2-2), immunoblotting assays were performed to determine 
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the specificity of the antibody.  
 
 
      1 mlprwelaly llaslgfhfy sfyevykvsr eheeeldqef eletdtlfgg lkkdatdfew 
 
       61 sfwmewgkqw lvwlllghmv vsqmatllar khrpwilmly gmwacwcvlg tpgvamvllh 
 
      121 ttisfcvaqf rsqlltwlcs llllstlrlq gveevkrrwy kteneyyllq ftltvrclyy 
 
      181 tnfslelcwq qlpaastsys fpwmlayvfy ypvlhngpil sfsefikqmq qqehdslkas 
 
      241 lcvlalglgr llcwwwlael mahlmymhai yssiplletv scwtlgglal aqvlffyvky 
 
      301 lvlfgvpall mrldgltppa lprcvstmfs ftgmwryfdv glhnfliryv yipvggsqhg 
 
      361 llgtlfstam tfafvsywHg gydylwcwaa lnwlgvtven gvrrlvetpc iqdslaryfs 
 
      421 pqarrrfhaa lascstsmli lsnlvflggd evgktywnri fiqgwpwvtl svlgflycys 
 
      481 hvgiawaqty atd 
Positively charged       Negatively Charged       Cysteine       Strong TM Helices 
Signal sequence         H, conserved His 
 
 
Figure 4-2. Suggested model for the transmembrane domains of hHhat. 
The sequences of two peptides used to generate hHhat antibody are 
underlined with blue lines. The potential transmembrane (TM) domains of 
hHhat are highlighted in yellow (C. Palmer, personal communication). 
Positively and negatively charged residues in the transmembrane domains are 
highlighted in red and light blue respectively. The histidine 379 residue 
conserved in almost all members of the MBOAT family (shown as H) may 
contribute to the active site of the putative acyltransferase. 
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4-2-2.  Characterisation of hHhat antibody 
To separate cytosolic and membrane-associated proteins, HEK293a cells were 
subjected to S100/P100 fractionation and immunoblotting. An hHhat-EGFP 
mammalian expression construct was prepared; the clone map is shown in Fig. 
4-3. To characterise the hHhat antibody, un-transfected, hHhat-EGFP- or 
mGup1-EGFP-transfected cells were subjected to subcellular fractionation 
followed by Western blotting (Fig. 4-4). Fig. 4-4A shows that a single protein 
(~32 kDa) was recognised by our hHhat antibody in the P100 but not the S100 
fraction, showing that this endogenous protein is membrane-associated. This 
molecular weight corresponds to that reported previously [211]. This is 
consistent with a multi-spanning protein with predicted size of 57 kDa showing 
increased mobility in SDS/PAGE due to elevated SDS binding. To examine the 
specificity of this antibody, we used hHhat-EGFP- or 
mGup1-EGFP-transfected HEK293a cells, and analysed them by 
immunoblotting for GFP and Hhat. Anti-GFP immunoblotting shows expression 
of mGup1-EGFP and hHhat-EGFP, representing the transfection efficacy (Fig. 
4-4B and C, left panel). Immunoblotting with anti-hHhat showed that this 
antibody recognised both endogenous hHhat and transfected hHhat-EGFP 
fusion protein (~58 kDa in Fig. 4-4B, right panel) but not exogenous 
mGup1-EGFP fusion. These results demonstrate the specificity of this 
antibody for hHhat without cross-reaction with mGup-1, another member of the 
MBOAT family which shares high homology to Hhat. 
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Figure 4-3. Restriction Map (A) and Multiple Cloning Site (MCS, B) of 
pEGFP-N3 (Unique restriction sites are in bold). The Not I site follows the 
EGFP stop codon. The Xba I site (*) is methylated in the DNA provided by BD 
Biosciences Clontech. Human Hhat cDNA and mouse Gup1 cDNA were 
inserted between XhoI and BamHI sites based on a PCR method as shown in I 
and II respectively.  
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Figure 4-4. Characterisation of hHhat antibody. A. S100/P100 separation in 
un-transfected HEK293a cells, showing that a single ~32 kDa protein was 
shown in total cell lysates is a membrane protein but not a cytosolic protein. T, 
total cell lysate; P, P100 membrane fraction and S, S100 cytosolic fraction. B 
and C show the specificity of our Hhat antibody; hHhat-EGFP- or 
mGup1-EGFP-transfected HEK293a cells were used. The left panel is a 
Western blot for GFP showing transfection efficacy, whereas the right panel 
shows a Western blot with anti-hHhat demonstrating that our hHhat antibody 
recognises both endogenous hHhat (~32 kDa) and hHhat-EGFP fusion protein 
(~58 kDa, shown by arrow) located in the membrane fraction, but not 
mGup1-EGFP fusion, a mouse homologue of Hhat. 
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4-2-3. Intracellular localisation of endogenous hHhat to ER 
To determine the intracellular localisation of endogenous hHhat in PANC1 cells, 
the hHhat antibody, anti-GM130 and anti-PDI were used for 
immunofluorescence confocal microscopy. Here, different patterns of Hhat 
staining in Fig. 4-5A and C (also Fig. 4-5B and D) were observed is the 
consequence of distribution of ER and Golgi complex appeared in vivo 
differently.  Confocal sectioning of stained PANC1 cells showed that the 
hHhat protein was primarily in the ER (Fig. 4-5A). Z-sections taken every 0.5 
µm through the cell showed little, if any, hHhat within the Golgi complex (Fig. 
4-5C).  These results were verified using hHhat-EGFP-transfected PANC1 
cells; a similar distribution was observed as for endogenous hHhat, confirming 
that hHhat localised mainly in the ER but not in Golgi apparatus (Fig. 4-5B and 
D). The Pearson product-moment correlation coefficients (kindly provided by 
Dr. Marek Cebecauer) are shown in Fig. 4-6 (**, P< 0.001).   
 
In statistics, the Pearson product-moment correlation coefficient (referred to as 
the PMCC, and typically denoted by r) is a measure of the correlation (linear 
dependence) between two random variables X and Y, giving a value between 
+1 (highly correlated) and −1 (completely uncorrelated). As expected, PMCC 
yielded significant linear dependence between endogenous Hhat and ER as 
well as between extrogenous Hhat-GFP and ER, but neither between 
endogenous Hhat and Golgi complex nor between extrogenous Hhat-GFP and 
Golgi complex. 
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Figure 4-5. Localisation of hHhat in PANC1 cells. Localisation of hHhat in 
PANC1 cells was indicated by confocal microscopy combined with 
immunofluorescence of endogenous hHhat (green in A, C), ER (red in A, B) 
and Golgi (red in C, D) markers; and the result was verified in 
hHhat-EGFP-transfected cells (green in B, D). Taking A/B and C/D together 
shows that endogenous hHhat and hHhat-EGFP show a similar distribution 
pattern in the cells, localising in ER mainly but not in Golgi apparatus. 
 
 
 
 
 
Figure 4-6. Pearson product-moment correlation coefficients (PMCC) for 
hHhat confocal microscopy. PMCC estimates the strength of the linear 
relationship between two random variables. The results here show 0.65 
±
 
0.13 in endoHhat/PDI, 0.67 
±
 0.20 in Hhat-GFP/PDI, 0.15 
±
 0.10 in 
endoHhat /GM130 and 0.12 
±
 0.11 in Hhat-GFP /GM130; confirm and 
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extend previously published data reporting the localisation of transfected 
Hhat-HA in COS-1 cells [12].   
 
 
 
4-2-4. Knocking down hHhat in PANC1 cells causes reduction 
in Shh palmitoylation and cellular retention 
To determine whether Hhat is essential for Shh palmitoylation, I established 
conditions for effective knockdown (KD) of hHhat in PANC1 cells and 
combined this with an in vitro Shh palmitoylation assay. The siRNA KD of 
hHhat was examined by immunoblotting of hHhat; α-tubulin was used as a 
loading control. In addition, to determine the specificity of hHhat siRNA two 
negative controls were used: a scrambled siRNA (Hhat-Scr) and a specific 
control mutated hHhat siRNA (Hhat-Mut) which contains mutations from the 
original hHhat siRNA in the 10th, 13th and 19th nucleotide to preclude siRNA 
activity. My results show that optimised hHhat RNAi KD results in a >70% 
decrease in hHhat protein expression in PANC1 cells (Fig. 4-7A and 4-7B), 
whereas with hHhat-Mut siRNA the hHhat protein level was unaffected, and 
similar results were observed with Hhat-Scr RNAi treatment (Fig. 4-7A and 
4-7B). 
 
Next, I established a cell-based Shh palmitoylation assay based on the 
Cu(II)-catalysed azido-alkyne cycloaddition (CuAAC) reaction, also called 
click-chemistry (The relevant reagents were kindly provided by Dr. Tate EW 
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and Jovanovic B) [181]. The traditional approach for tracking protein 
lipid-modification is based on radioisotopic labelling which has often been 
considered time-consuming, usually taking days, weeks or even months to 
process. As an alternative approach, click-chemistry was used here. 
Click-chemistry was defined as bond-forming reactions useful for rapid 
assembly of molecules with desired function [242]. Copper and ruthenium are 
the catalysts commonly used in the reaction. Copper catalysts (Fig. 2-1) 
accelerate the reaction of azides with terminal alkynes by ~107 relative to the 
uncatalysed version, making it conveniently fast at room temperature [234]. 
These transformations are easy to perform, give rise to their intended products 
in very high yields with little or no byproducts, and is insensitive to oxygen and 
water.  In fact, in several instances water is the ideal reaction solvent, 
providing the best yields and highest rates [233].  
 
In short, in this study proteins metabolically incorporate the palmitate analogue 
heptadec-16-ynoic acid (YnC15) and are detected following reaction with an 
azido-TAMRA-biotin tag. Palmitoylation can be monitored by fluorescence 
imaging of the tag and also by anti-Shh immunoblotting which detects a slightly 
larger Shh band due to tag addition. The fluorescence result (Fig. 4-7C) shows 
a single ~22 kDa fluorescent protein, YnC15-Shh-N, immunoprecipitated by 
anti-Shh 5E1 from both cell lysates and medium. In addition, this fluorescent 
protein was more abundant after hHhat-Mut RNAi treatment compared to 
hHhat KD treatment, indicating that knocking down hHhat inhibits palmitate 
analogue YnC15 incorporation into endogenous Shh. Moreover, the same 
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samples were examined by immunoblotting for Shh; in both culture medium 
and cell lysates, YnC15-Shh was detected as a ~22 kDa protein (shown by 
arrow in Fig. 4-7C). In the hHhat KD cell lysate, there was less YnC15-Shh 
compared to the hHhat-Mut sample, corroborating the result with fluorescence 
imaging. On the other hand, in the medium from hHhat KD cells there was 
more Shh (~19 kDa) compared with cells treated with hHhat-Mut RNAi (Fig. 
4-8E), suggesting that knocking down hHhat enhances Shh release into the 
medium, albeit presumably in unacylated form. Combined with the fact that 
less endogenous Shh was observed in lysates from hHhat KD cells compared 
to hHhat-Mut-treated cells, this supports the interpretation that knocking down 
hHhat suppresses Shh retention. 
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Figure 4-7. hHhat RNAi knockdown in PANC1 cells. To examine hHhat 
RNAi KD efficacy in PANC1 cells, a Western blot for Hhat was processed after 
24hr, 48hr and 72hr siRNA transfection. Tubulin was used a loading control 
(lower panel in A). Quantitative results are shown in B. To confirm the role of 
hHhat in Shh palmitoylation, click-chemistry was carried out to detect 
palmitoylation in vivo (C). After 5E1 immunoprecipitation (IP, right), YnC15 (a 
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palmitate analogue)-labeled Shh was detected as a single band by 
fluorescence (arrow). Compared to Hhat-Mut-treated cells, YnC15-Shh was 
reduced in hHhat KD condition in both medium and cell lysates, suggesting 
that hHhat KD decreases Shh palmitoylation in this in vitro assay. 
 
 
 
4-2-5. Knocking down hHhat causes decreased signalling 
through the Shh pathway in PANC1 cells 
To determine whether hHhat (and hence palmitoylation of Shh) is required for 
Shh signalling activity, semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) and immunoblotting were performed on a hHhat KD 
time-course experiment; GAPDH and β-Actin were used as loading controls. In 
hHhat KD conditions, both Patched (Ptc) and Gli1 were found to be decreased 
in mRNA level by >70% and >50% respectively, whereas Shh and 
Smoothened (Smo) showed no significant difference (Fig. 4-8A and B). 
Immunoblotting was carried out to verify these results at the protein level, 
showing that hHhat decreased up to 70% in protein level after hHhat siRNA 
treatment, while Ptc and Gli1 were reduced by ~70% and ~50% respectively 
(Fig. 4-8C and D), consistent with RT-PCR. All these data suggest that 
knocking down hHhat causes decreased signalling though the Shh pathway in 
PANC1 cells. Interestingly, when I examined Shh by immunoblotting of cell 
lysates, cell-associated Shh was reduced ~70% in hHhat KD cells (Fig. 4-8E). 
This reduction is not due to alteration in Shh mRNA level (Fig. 4-8A) but by 
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reduced protein association with the cell membrane, supporting the previous 
suggestion that un-palmitoylated Shh has reduced ability in cell membrane 
association. 
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Figure 4-8. Effect of hHhat on Shh modification and signalling in PANC1 
cells. To study the role of hHhat in Shh signalling, expression level of Ptc and 
Gli1 were examined by both RT-PCR and Western blot after hHhat KD (A, C). 
Quantification is provided in B and D. Interestingly, cell-associated Shh is 
reduced after hHhat KD (C, bottom panel) but Shh mRNA level remains 
unchanged (A), suggesting that hHhat KD reduces Shh retention to cell 
membranes. In E, 48hr after RNAi KD samples were labeled with YnC15 (a 
palmitate analogue) for 48hr and processed by click-chemistry, then medium 
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and cell lysates were collected for 5E1 immunoprecipitation and analysed by 
Shh Western blot. In both medium and cell lysates, YnC15-labeled Shh is 
much lower in hHhat KD group than in Hhat-Mut and control group, providing a 
consistent result with Fig. 4-6C. On the other hand, non-YnC15-labeled 
secreted Shh is more abundant in the hHhat KD cells but less abundant as cell 
associated form in cell lysates. Combining both observations suggests that 
un-palmitoylated Shh has lost ability in cell association, but instead is released 
to the medium. 
 
 
 
4-2-6. PANC1 proliferation is Shh-dependent and inhibited by 
knocking down hHhat 
To determine the effects of hHhat on PANC1 proliferation, hHhat RNAi KD 
combined with CFSE incorporation were used, followed by flow cytometry 
analysis, as described in Chapter 3 (practical assistance and advice was 
generously provided by Dr. Marek Cebecauer). In the assay, I set out to 
investigate whether PANC1 proliferation is Shh-dependent by treating cells 
with 5E1 inhibitory antibody for Shh. The results (Fig. 4-9F) have been 
discussed previously in Section 3-2-6 showing that PANC1 proliferation is 
Shh-dependent. 
 
Interestingly, 7 days after transfection hHhat siRNA-treated cells had a 
significantly higher mean fluorescence intensity (MFI), with ~8 times greater 
CF fluorescence (>6000) compared to hHhat-Mut siRNA-transfected cells 
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(<1000) (Fig. 4-9F). In addition, the flow cytometry profile shows that there are 
two significant populations in the hHhat RNAi group but only one population in 
the hHhat-Mut RNAi group and untreated cells (Fig. 4-9A, D and E). These 
results indicate that siRNA-mediated KD of hHhat suppresses PANC1 cell 
proliferation substantially. 
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Figure 4-9. The role of hHhat in PANC1 cell proliferation. The histogram of 
flow cytometry is shown in A-E. The quantitative result is shown in F. 5E1 
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treatment on Day 1 (5E1 D1, B) was used to examine if PANC1 proliferation is 
Shh-dependent. 5E1 treatment on Day 4 (5E1 D4, C) was used to mimic RNAi 
KD in vivo (which is carried out for 72hr). The level of maximum labeling was 
observed by treating cells with CFSE just before flow cytometer assessment. 
To study the effect of hHhat in PANC1 proliferation, 8 days after RNAi 
transfection the cells were applied to the flow cytometer. In A-E, the X-axis 
shows the CF intensity. The green arrow shows the direction of peak shift 
observed when cells proliferate. In F, the Y-axis shows the CF intensity 
observed from 30,000 cells. The experiments were repeated three times in 
triplicate, and statistical significance was measured by using the two-tailed t 
test (*, P< 0.00001; **, P< 0.0001). 
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4-2-7.  Knocking down hHhat inhibits PANC1 invasion 
To investigate the contribution of hHhat to the invasive potential of PANC1 cells, 
I carried out invasion assays after Hhat knockdown. Initially, I showed that 
PANC1 invasion is dependent on Shh signalling using 5E1 treatment. The 
results (Fig. 4-10) have been discussed previously in Section 3-2-7, 
suggesting that the invasive ability of PANC1 cells is dependent on Shh 
signalling. Moreover, PANC1 cells were transfected with hHhat siRNA 72hr 
prior to the invasion assay. The reason why 72hr was chosen here is due to 
optimised condition for reduced Shh signalling in PANC1 cells caused by Hhat 
KD was observed on 72hr after siRNA transfection (Fig. 4-8 C and D). In this 
assay I observed a significant decrease in the number of invasive PANC1 cells 
(66
±
7 cells/well), a level similar to that observed for the 5E1 treatment (Fig. 
4-10). In contrast, Hhat-Mut siRNA control treatment gave similar levels as 
observed in untreated control cells (276
±
40 cells/well). These results indicate 
that expression of hHhat was required for efficient PANC1 invasion. 
Importantly, direct cell growth assays showed that the doubling time for 
PANC1 cells is ~51hr. The four-fold reduction in invasion observed in 24hr 
cannot therefore be fully accounted for by inhibition of cell growth. 
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Figure 4-10. Biological function of hHhat in PANC1 cell invasion. I set out 
to determine whether PANC1 invasion is Shh dependent using 5E1 treatment. 
To study the effect of hHhat in PANC1 invasion, 72hr after RNAi transfection 
the cells were plated onto Matrigel invasion chambers for 24hr. Cells that had 
migrated from the upper to the lower side of the filter were photographed (A) 
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and counted with a light microscope (40 fields/filter, B). The experiments were 
repeated four times, and statistical significance was measured by using the 
two-tailed t test (*, P< 0.001; **, P< 0.0001). 
 
 
 
4-2-8. Knocking down hHhat in PANC1 cells reduces 
endogenous Shh oligomerisation 
To evaluate the role of hHhat in formation of Shh multimeric complexes, gel 
filtration followed by Shh dot blotting were carried out on PANC1 conditioned 
medium. To confirm the specificity of the Shh antibody, H160, which was to be 
used for dot blotting, it was tested against different culture media by Western 
blotting (Fig. 4-10A). The result shows that no detectable non-specific 
background was observed. In Shh dot blots (Fig. 4-11B), most secreted Shh in 
control PANC1 culture medium migrates as large multimeric complexes and 
only a small portion of Shh migrates as monomers (2.6
±
1.2%, P< 0.0001), 
similarly to a previous study [188]. I then analysed whether hHhat was involved 
in this multimeric complex formation by hHhat siRNA treatment. Interestingly, 
in conditioned medium from hHhat siRNA-treated cells, significant quantities of 
Shh monomers were detected (41.2
±
9.6%, P< 0.0001), nearly 20 times 
higher than in control medium, whereas Hhat-Mut siRNA-treated medium 
shows a similar pattern to control medium with only 2.1
±
1.5% (P< 0.0001) 
monomer. These data suggest that KD of hHhat in PANC1 cells causes 
decreased Shh multimer secretion and further implies that palmitoylation of 
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Shh plays a positive role in Shh multimer formation. 
 
 
 
 
 
Figure 4-11. The role of hHhat in Shh multimeric complex formation. 72hr 
after RNAi transfection, the culture media were TCA precipitated and 
examined by Western blot of Shh (A). The result confirmed previous data (Fig. 
4-8E), showing that un-palmitoylated Shh (Hhat KD group) is more abundant in 
the medium. In B, to examine the role of hHhat in Shh oligomerisation, 72hr 
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after RNAi transfection the media were subjected to gel filtration 
chromatography (Superdex200 10/300 GL column). After TCA precipitation, 
the fractions were probed by Shh dot blot (B). Monomerisation factor (%) = 
(Monomer / Monomer + Multimer) X 100%. 
 
 
 
4-3.  Discussion 
Hedgehog proteins are unusual in being dually lipid-modified to be fully active. 
The lipidations are essential for efficient morphogen secretion, travel through 
the ECM, and accurate targeting on receiving cells. In this work, using an 
anti-peptide strategy we generated a human Hhat antibody which is the first 
antibody specific to Hhat. The specificity of this antibody was confirmed with 
immunoblotting using hHhat-EGFP- and mGup1-EGFP-transfected cells. In 
addition, this antibody was characterised by subcellular fractionation 
(S100/P100) showing that hHhat localised in the membrane fraction instead of 
the cytosolic fraction. Also, using this self-generated hHhat antibody combined 
with confocal microscopy, I found that in PANC1 cells endogenous hHhat 
localises in ER mainly but not in Golgi complex. Combined with a previous 
study showing that HA-tagged Hhat and Shh co-localised in the secretory 
pathway [12] in COS-1 cells, this suggests that palmitoylation of Shh occurs in 
the lumen of the ER. This is the first evidence showing the localisation of 
endogenous Hhat in vivo. 
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It has been reported that lipidations of Hh/Shh are essential for efficient 
morphogen secretion and appropriate travel through the ECM. Also, Hhat is 
identified as an enzyme directly and specifically required for the N-terminal 
addition of palmitate to Hh/Shh morphogens, and is believed to play an 
essential role in effective production of the Hh/Shh proteins [31,164]. Instead 
of using a traditional approach based on radiolabelled 3H-palmitate 
incorporation, in this work I used an in vitro Shh palmitoylation using 
click-chemistry. The data presented in this study indicate that hHhat is 
responsible for Shh palmitoylation, showing a consistent result with studies in 
both Drosophila melanogaster and mammalian systems [164]. In addition, in 
this work I established conditions for effective RNAi KD of hHhat in PANC1 
cells and found that it causes reduced signalling through the Shh pathway in 
PANC1 cells via examining Ptc and Gli1 expression, both target genes of Shh 
signalling. The KD efficacy was examined by Western blot of hHhat and the 
cell-based palmitoylation method. The protein levels of Ptc and Gli1 drop 
~70% and ~50% respectively after hHhat KD, in agreement with mRNA 
reduction by >70% and >50%. The data presented herein provide the first 
direct evidence showing the functional role of Hhat in Shh signalling in a 
human model system.  
 
In previous studies by Segal et al., ShhAla/Ala and ShhAla/- mice show abnormal 
proliferation in cerebellar size, indicating suppressed neural stem/precursor 
cell proliferation in multiple locations in both the developing and adult CNS 
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caused by inefficient Shh signalling. In this study, due to the fact that 
pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive of all 
cancers and is relatively resistant to medical treatments, we asked whether the 
decrease in palmitoylation of Shh is reflected in abnormal proliferation in 
human PDAC (PANC1) cells. In 5E1-treated PANC-1 cells, proliferation was 
strongly suppressed shown by highly maintained CF level observed, indicating 
Shh-dependent PANC1 proliferation. Furthermore, in hHhat KD cells PANC1 
proliferation was approximately 3 times less than that in un-treated cells and 
Hhat-Mut-treated cells throughout the 8-days experiment. This decreased 
proliferation suggests that N-terminal palmitoylation of Shh promotes 
mitogenesis of PANC1 cells through Shh signalling. This is the first direct 
demonstration of reduced cell proliferation caused by Hhat KD in a mammalian 
system. 
 
It has been reported that Hh/Shh signalling acts as a contributor to various 
tumour types e.g. pancreatic cancer, colon carcinoma, gastric cancer, small 
cell lung cancer (SCLC), prostate cancer, breast cancer and basal cell 
carcinoma [38,42,84,91-96,109,178,213]. Although it has been revealed that 
the Hh/Shh signal participates in cell migration and angiogenesis processes 
and is correlated with the severity of the associated tumour, especially the 
invasiveness of three human PDAC cell lines (AsPC-1, SUIT-2, and CFPAC-1) 
[212], to date no report gives a detailed description on the functional relevance 
of the Shh pathway to invasion of human pancreatic cancer PANC1 cells. In 
the present study, Shh signalling inhibition with 5E1, the inhibitory antibody of 
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Shh, reduces the invasion ability of PANC1 cells, indicating PANC1 that 
invasion is Shh-dependent. Moreover, the invasive ability of these cells was 
abolished by hHhat KD indicating that the palmitoylation of Shh plays a 
significant role in Shh signalling which results in Matrigel degradation and cell 
migration through the ECM. Here, I observed for the first time that Shh 
signalling is associated significantly with invasion of PANC1 cells. To sum up, 
hHhat is required for effective Shh signalling via adding a palmitate to the 
N-terminus of Shh, and is necessary for Shh-dependent PANC1 proliferation 
and invasion. Therefore, this study provides a novel perspective in which 
hHhat could be an effective therapeutic target in human pancreatic cancer 
treatment. 
 
Changes in association to cell membranes and ability in multimeric complex 
formation provide two possible mechanisms by which palmitoylation of Shh 
could modulate signalling activity. In this work, the data from click-chemistry 
method reveal that un-palmitoylated Shh protein lost ability in cell association. 
On the other hand, the Shh oligomerisation assay provides strong evidence 
that palmitoylation plays a significant contribution in Shh multimeric complex 
formation. In addition to the evidence listed above, both blocked proliferation 
and invasion are in agreement with malfunction of Shh signalling caused by 
hHhat KD. Based on these observations, I hypothesise that reduced Shh 
palmitoylation causes the loss in cell retention and Shh oligomerisation, 
leading to inhibited cell proliferation and invasion. 
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CHAPTER 5 
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5. Summary, Final Discussion and Future Directions 
 
5-1. Clinical treatments of PDAC 
About PDAC. Pancreatic ductal adenocarcinoma (PDAC) remains one of the 
most difficult cancers to treat. About 95% of exocrine pancreatic cancers are 
adenocarcinomas. It is the commonest cancer affecting the exocrine pancreas.  
Without active treatment, metastatic pancreatic cancer has a median survival 
of 3–5 months and 6–10 months for locally advanced disease, which increases 
to around 11–15 months with resectional surgery [226]. Due to the late 
presentation and aggressive tumour biology of this disease, only a minority 
(10–15%) of patients can undergo potentially curative surgery.   
 
Treatment of pancreatic cancers. PDAC is highly resistant to conventional 
methods of cytotoxic treatment and radiotherapy. Few chemotherapeutic 
agents have been shown to have reproducible response rates of more than 
10%. 5-Fluorouracil (5FU) is an inhibitor of thymidylate synthetase (essential 
for synthesis of DNA nucleotides) and has been widely used in advanced 
pancreatic cancer, with a median survival of around 5–6 months [230]. Though 
radiotherapy has also been widely used for the treatment of pancreatic cancer, 
a recent meta-analysis demonstrated that chemoradiotherapy is better than 
radiotherapy alone and that there is no survival difference between 
chemoradiotherapy plus follow-on chemotherapy and chemotherapy alone 
[230]. A number of new agents (e.g. PA3, SWOG S0205, CALGB 80303, Avita, 
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GV1001 and TeloVac) have been developed from the molecular understanding 
of pancreatic cancer, which are now being assessed in large phase III trials in 
advanced pancreatic cancer [223,229].  Radical resection alone will result in 
a 5-year survival of only 10% owing to recurrence after surgery [231]. Nearly 
all patients develop metastatic disease, most commonly of the liver and 
peritoneum but also the lungs, and this may occur with or without local 
recurrence.  To sum up, significant progress has been made in illuminating 
risk factors and key molecular events in pancreatic carcinogenesis, but still, at 
present only pancreatic resection can improve survival significantly. A further 
improvement in survival is achievable with adjuvant chemotherapy but not 
chemoradiotherapy. Though surgical approaches have become more 
standardised and are safer, with much improvement in both morbidity and 
mortality in specialised centres, surgery of pancreatic cancer can only be 
performed within a regional pancreas cancer. Therefore, there is a great need 
in development of earlier diagnosis, screening of high-risk groups and efficient 
treatment of pancreatic cancer.  
 
Shh signalling in PDAC. Sonic hedgehog (Shh) signalling plays a crucial role 
in the initiation and growth of pancreatic cancer [103-106].  Cyclopamine 
inhibits the Shh pathway through direct interaction with Smoothened [214] and 
has now entered early clinical trial development. Recent studies suggest Shh 
may also act as a contributor to so-called pancreatic cancer stem cells [227]. Li 
et al have recently identified a CD44+CD24+ESA+ phenotype (0.2–0.8%) 
isolated from primary pancreatic cancer cells with a 100-fold increased 
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tumourgenic potential [227]. The existence of cancer stem cells is based on 
the hypothesis that the ability of a tumour to grow and propagate is dependent 
on a small subset of cells (< 5%) with special properties, which like normal 
stem cells, have a great potential for self-renewal and production of 
differentiated progeny [228].  
 
5-2. The role of HSPGs in hShh signalling 
To investigate the interaction between hShh and heparan sulfate 
proteoglycans (HSPGs) and clarify the biological function of hShh/HSPGs 
complexes in hShh signalling, in this study, 
I took an alternative approach by generating mutant Shh proteins that cannot 
bind heparin properly. I used DNA mutagenesis (based on modelling of the 
hShh-heparin interaction by Dr. Barbara Mulloy, NIBSC, personal 
communication) and heparin affinity chromatography to determine key 
residues in hShh involved in heparin binding (K37/38 and K178). The above 
data showed for the first time that, besides the Cardin-Weintraub motif, K178 
of hShh also plays a significant role in HSPGs binding. 
 
Also, by detecting induced Alkaline Phosphatase activity in C3H10T1/2 cells 
and hShh-inducible genes expression in PANC1 human PDAC cells via 
immunoblotting and semi-quantitative RT-PCR analysis as a readout; I 
examined the biological function of mutated hShhs (ShhNC24IIK37/38S, 
K178S and K37/38/178S) that cannot interact with heparin efficiently, and 
showed that they promoted lower signalling activity compared to wild-type 
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hShh and a control mutation (ShhNC24IIK74S). Together, these findings 
indicate that Shh-HSPGs interactions mediated by the Cardin-Weintraub motif 
and the novel residue 178K are significantly required for Shh signalling activity. 
 
In addition, in this study employed 5E1 to block the Shh signalling pathway in 
PANC1 cells and to determine the effect of the pathway on proliferation and 
invasiveness of PANC1 cells, showing the first direct evidence that Shh 
signalling has a critical and central role in PANC1 cell growth and contributes 
to malignant transformation. Furthermore, I tested the effect of mutant hShh 
proteins on proliferation and invasion of PANC1 cells following endogenous 
hShh RNAi knockdown. These findings indicate that Shh-HSPGs interactions 
promote PANC1 cells oncogenic properties at multiple levels, including both 
proliferation and invasion; providing corresponsive results to previous studies, 
including: 1) Several Shh responsive genes; e.g. Gli2, N-myc, Gli3, Cyclin D1, 
Cyclin D2 and Bmi-1, have been identified, including genes that are involved in 
proliferation and tissue patterning [196-202]. 2) Cyclin D1, Cyclin D2 and 
Bmi-1 gene targets that require Shh-HSPG interactions are significant in 
tumour stem cell biology [196,197]. 3) Shh-dependent cancer growth can be 
stimulated via glypican overexpression in several cases, e.g. prostate cancer, 
PDAC and rhabdomyosarcoma [203,204]. However, using a mammalian 
expression vector to preclude the possibility of misfolding of purified proteins 
would provide a better approach to examine the biological function of mutated 
Shh proteins which cannot bind to heparin properly.  
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Lastly, I used gel filtration chromatography to study the role of mutated hShhs 
in Shh multimeric complex formation. From the data obtained, here I 
hypothesise for the first time that K178 of Shh may play key role in Shh 
multimeric complex formation via binding with HSPGs. Supportive evidence is 
that in the 3D structure of Shh, K178 is located close to the HSPG-binding 
groove containing the Cardin-Weintraub motif (Dr. K. Grobe, personal 
communication). 
 
These results must be considered with previous studies using mutations in the 
glypican Dally-like, mutations in the Ext gene family (the HSPG-synthesising 
enzymes) and truncation of the Cardin-Weintraub motif; which have suggested 
that HSPGs are critical for appropriate localisation of Hh proteins 
[55,138,139,206]. Here, I hypothesise a second potential mechanism to 
explain the effects of proteoglycans on Shh-induced proliferation and invasion 
in PANC1 cells - Shh-HSPGs interactions stimulate Shh signalling via forming 
stablised multimeric complexes in ECM to facilitate stability and solubility of 
Shh proteins. 
 
To sum up, the data provided in this study indicate that the gene expression 
pattern induced by Shh is modulated by proteoglycans of producing cells via 
forming stablised multimeric complexes in ECM. Moreover, Shh target genes 
that are altered when cells are stimulated by different Shh proteins include 
many that have been implicated in proliferation and oncogenesis.  
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Specific achievements in the study are listed below: 
 Determined key residues, including a known heparin binding motif K37/38 
and a novel residue - K178, of Shh involved in heparin binding. 
 Showed reduced biological function in C3H10T1/2 model system 
stimulated by mutated Shh which cannot interact with heparin efficiently 
and verified the result with 5E1 (an inhibitory antibody specific to Shh) 
treatment. 
 In PANC1 cells, Immunoblot and RT-PCR of Ptc and Gli1 showed a 
consistent result with C3H10T1/2 system. 
 wtShh and control mutant (K74S) can restore PANC1 division and 
invasion caused by Shh KD, but not triple mutant - ShhK37.38.178S. 
 Used endogenous Shh KD to study the role of exogenous mutated Shh in 
Shh multimeric complex formation by gel filtration. 
 
5-3. Characterisation of hHhat in PANC1 cells 
To identify the intracellular localisation of hHhat in mammalian cells, I 
characterised an hHhat antibody prepared in the lab which is the first antibody 
specific to Hhat. By subcellular fractionation and Western blotting hHhat is 
found to be a membrane protein. Also, I confirmed the specificity of the 
antibody using a self-constructed hHhat-EGFP clone, and a control 
mGup1-EGFP clone using immunoblotting. In addition, I used the hHhat 
antibody to determine the intracellular localisation of hHhat in PANC1 cells by 
confocal microscopy and showed that hHhat localised in ER mainly but not in 
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Golgi apparatus. This results suggest that palmitoylation of Shh occurs in the 
lumen of the ER. I confirmed this using the hHhat-EGFP clone for fluorescence 
microscopy in transfected cells. Combined with the previous localisation study 
carried out by HA-tagged exogenous Hhat in COS-1 cells [12], the work here 
provides the first evidence for the localisation of endogenous hHhat in vivo. 
 
Specific accomplishments in the study are listed below: 
 Characterised hHhat antibody by subcellular fractionation and Western 
blotting. 
 Confirmed the specificity of the antibody using a hHhat-EGFP clone, a 
control mGup1-EGFP clone and immunoblotting. 
 Determined the intracellular localisation of hHhat in PANC1 cells by 
confocal microscopy and showed that hHhat co-localised in ER mainly but 
not in Golgi apparatus and verified via the hHhat-EGFP clone for 
fluorescence microscopy in transfected cells. 
 
5-4. The role of hHhat in hShh signalling 
To illuminate the biological function of palmitoylation of hShh in production of 
active hShh and in the formation of hShh multimeric complex, I optimised 
hHhat RNAi KD in PANC1 cells and confirmed by an in vitro palmitoylation 
assay, click-chemistry method, showing a consistent result with studies in both 
Drosophila melanogaster and mammalian systems in which Hhat is required 
for the N-terminal addition of palmitate to Hh/Shh morphogens [12,31].  
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Next, using semi-quantitative RT-PCR and immunoblot analyses, I examined 
the role of hHhat in production of active hShh, which causes decreased 
signalling through the Shh pathway in PANC1 cells, providing the first direct 
evidence for the functional role of Hhat in Shh signalling in a human model 
system. Here, Hhat’s role as a positive mediator in Shh signalling may be 
caused by its potency in increasing cell retention. To confirm this possibility, I 
investigated the effect of the addition of palmitate to hShh on its secretion from 
producing cells (or attachment to receiving cells) by comparing cell-associated 
hShh in cells that have hHhat silenced by RNAi oligonucleotides with control 
cells. The click-chemistry assay and Shh immunoblotting data both suggest 
that un-palmitoylated Shh protein lost ability in cell association, providing 
consistent results with previous findings in Drosophila [31]. Palmitoylation of 
Shh can improve its ability to associate to cell membranes, providing a 
possible mechanism by which palmitoylation of Shh could modulate the 
signalling activity.  
 
In Drosophila, RNAi-mediated Hhat KD reduces N-terminal palmitoylation of 
Hh in vivo and causes a reduction in cell association as indicated by a 
significant increase in release of Hh protein into the culture medium [31]. 
Furthermore, in my study using hHhat RNAi KD, gel filtration of high molecular 
weight complexes of hShh and immunoblotting of hShh I characterised the role 
of palmitoylation of hShh in hShh multimeric complex formation. The results 
provide strong evidence that the palmitoylation is involved in Shh multimeric 
complex formation. This result also gives another possible mechanism by 
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which palmitoylation of Shh could modulate signalling activity, by changing its 
ability in multimeric complex formation and increasing proteins stability in 
ECM. 
  
It has been shown previously that the Hh/Shh signal participates in cell 
migration and angiogenesis processes and is correlated with the severity of 
the associated tumour, especially the invasiveness of three human PDAC cell 
lines (AsPC-1, SUIT-2, and CFPAC-1) [212]. However, no report has given a 
detailed description on the functional relevance of the invasion and 
proliferation of human PDAC PANC1 cells to the Shh pathway. In this study, 
5E1-treatment of PANC1 cells indicates that invasion and proliferation is 
Shh-dependent. Notably, I investigated the effect of Hhat KD on PANC1 
proliferation and invasion showing that knocking down Hhat represses PANC1 
proliferation and invasion. These data suggest that N-terminal palmitoylation of 
Shh promotes mitogenesis of PANC1 cells through Shh signalling, and give 
the first direct demonstration of reduced cell proliferation and invasion caused 
by Hhat KD in a mammalian system. To sum up, hHhat is required for effective 
Shh signalling via adding a palmitate to the N-terminus of Shh, and is 
necessary for Shh-dependent PANC1 proliferation and invasion. 
.  
Combining the above observations, I hypothesise that reduced Shh 
palmitoylation causes the loss in cell retention and Shh oligomerisation, 
leading to inhibited cell proliferation and invasion in PANC1 cells.  
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Specific achievements in this project are listed as following: 
 Established conditions for effective knockdown of hHhat – causes 
decreased signalling through the Shh pathway in PANC1 cells.  
 Knocking down Hhat inhibits PANC1 proliferation and invasion. 
 Studied the role of Shh palmitoylation in Shh multimeric complex formation 
and cell retention. 
 
5-5. Future perspective  
Dysregulation of Hh/Shh signalling pathway leads to carcinogenesis as 
mentioned in Section 1-1-4, and Hh/Shh signalling components are 
pharmacogenomics targets. Furthermore, loss-of-function mutations in 
negative regulators of the pathway, including Ptc1 and SuFu, have been 
associated with tumorigenesis, indicating the potential of inhibitors of Hh 
signalling act as tumour suppressors, as follows.  1) The Veratrum alkaloid 
cyclopamine functions as a Hh/Shh signalling inhibitor via binding to Smo and 
inducing Smo misfolding within the ER [214]. 2) The synthetic 
cyclopamine-derivative cyclopamine-KAAD, with increased potency for 
Hh/Shh signalling inhibition, is being applied as an anti-cancer drug clinically 
[215]. 3) SANT1-4 and Cur61414 are also small-molecule compounds which 
inhibit Hh/Shh signalling through binding to Smo [8,216]. 4) Other 
small-molecule modulators, inhibiting the signalling pathway mostly at the level 
of Smo, were also identified, supporting that Hh/Shh signalling pathway can be 
blocked at different levels [217]. On the other hand, to increase the potency for 
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inhibition in Hh/Shh signalling and to decrease the occurrence of drug 
resistance, a cocktail of Hh/Shh inhibitors could be developed as novel 
therapeutics for human cancer treatment. In this work, my studies provide a 
firm basis for understanding the functional roles of hShh palmitoylation and its 
interactions with HSPGs, and provide proof-of-principle for targeting these 
aspects of hShh biology in tumour cell therapeutics, specifically in the 
pancreatic carcinoma context. 
 
On one hand, since hHhat is required for effective Shh signalling via adding a 
palmitate to the N-terminus of Shh, and is necessary for Shh-dependent 
PANC1 proliferation and invasion, this study provides a novel perspective in 
which hHhat could be an effective therapeutic target in human pancreatic 
cancer treatment. On the other hand, the HSPGs seem to play a key role in 
regulating Shh stability, movement and reception through the ECM via forming 
multimeric complexes, leading to the following questions. Is the degree of 
sulphation on the HS GAG chains involved? Is cholesterol on Shh also 
significant in this multimeric complex formation? Do unidentified enzymes 
together with HSPGs regulate signalling? As a summary, a current model 
demonstrating the regulation of Shh signalling in mammalian cells is presented 
in Fig. 5-1. In the future, it would be interesting to find out the mechanism of 
this multimeric complex formation, and specific HSPG(s) involved in Shh 
signalling in tumour cells, which would provide further insight into the workings 
of the signalling pathway and the exploration of the therapeutic potential of Shh 
pathway inhibitors. Also, it would be helpful to build up gene-expression 
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profiles of human tumours in determining which cell types have activated 
Hh/Shh signalling and therefore be useful in predicting the outcome of 
potential treatments with Hh/Shh pathway inhibitors.  
 
To sum up, the findings in this work are exciting as inhibition of the pathway 
could lead to novel therapeutic approaches to primary and metastatic tumours. 
This is particularly important as the high frequency of metastasis in PDAC 
during early stages of the disease, often before diagnosis, is one of the 
complications that contribute to low survival rates [218]. 
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Figure 5-1. A model for Shh signalling regulation in mammalian cells. In 
the Shh producing cell (upper), Shh is synthesised as a full-length precursor 
(Shh-FL) in the ER. After its signal peptide is removed co-translationally, a 
palmitate is added to the N-terminus of Shh via Hhat in the ER lumen, followed 
by autocleavage and C-terminal cholesterol modification to form a fully 
modified Shh protein (ShhNp). After trafficking from internal membranes to 
plasma membrane, the ShhNp secretes to the ECM and forms multimers with 
HSPGs and Shifted (the Wnt inhibitory factor homologue [146]. Dispatched 
(Disp) is believed to be involved in this secretion.  On the signal-activated 
receiving cell (right bottom), Shh-HSPGs-Shifted multimers bind to Ptc and 
Glypican-5 (GPC5) [232] leading to internalisation of the complex and 
activation of Smo. On the contrary, in the signal-inhibited receiving cell (left 
bottom), Ptc, Hhip and Glypican-3 (GPC3) compete for binding to Shh. When 
Shh binds to GPC3 it is followed by GPI-dependent endocytosis, as a 
consequence Shh is removed from cell surface, prevented from binding to Ptc 
leading to downregulated signal transduction.    
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